[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 789
1. Al-Saad S, Al-Shibli K, Donnem T, Andersen S, Bremnes RM, Busund LT: Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients. J Thorac Oncol; 2010 Oct;5(10):1536-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
  • INTRODUCTION: To compare the efficacy of silver in situ hybridization (SISH) and immunohistochemistry (IHC) in detecting HER2 alterations and to investigate the prevalence and prognostic significance of Erb family members in non-small cell lung cancer (NSCLC).
  • METHODS: Stage I to IIIA tumors from 335 patients with NSCLC were immunohistochemically tested for protein expression of all Erb family members.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Gene Dosage. Genes, erbB-2 / genetics. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / therapy. Chromosomes, Human, Pair 17 / genetics. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Receptor, Epidermal Growth Factor / metabolism. Retrospective Studies. Tissue Array Analysis


2. In KH, Kwon YS, Oh IJ, Kim KS, Jung MH, Lee KH, Kim SY, Ryu JS, Lee SY, Jeong ET, Lee SY, Yum HK, Lee CG, Kim WS, Zo JI, Kim H, Kim YW, Kim SK, Lee JC, Kim YC: Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry Study. Lung Cancer; 2009 May;64(2):232-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry Study.
  • PURPOSE AND METHODS: The outcomes of lung cancer patients who were asymptomatic at diagnosis have never been reported as part of a large-scale study.
  • A national survey of lung cancer in South Korea registered a total of 8788 patients diagnosed in 2005.
  • We report the results herein, with an emphasis on the prognosis of the asymptomatic lung cancer patients.
  • RESULTS: Adenocarcinoma was the most frequent (36.1%) histopathologic type, followed by squamous cell carcinoma (32.1%), large cell carcinoma (1.5%), and small cell carcinoma (13.5%).
  • In most cases, lung cancer was detected with subjective symptoms, but 6.5% of cases had no symptoms indicative of lung cancer at the time of diagnosis.
  • Compared to symptomatic patients, asymptomatic patients were younger, more often female, non-smokers, and more frequently presented with adenocarcinoma.
  • Absence of symptoms at diagnosis significantly reduced the risk of death from non-small cell lung cancer, regardless of patient age, patient gender, stage at diagnosis, smoking history, or whether treatment was performed, but did not reduce the risk of death from small cell lung cancer.
  • CONCLUSIONS: Adenocarcinoma has grown to be the leading histopathologic type of lung cancer in South Korea.
  • Absence of symptom at diagnosis is a favorable prognostic factor for patients with non-small cell lung cancer.
  • [MeSH-major] Lung Neoplasms / mortality. Lung Neoplasms / pathology. Registries

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18809225.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


3. Zhao S, Shao K, Ye B, Liu X, Cheng G, Sun K, Meng P, He J: [Prognostic factors for survival after lung cancer surgery in elderly patients]. Zhongguo Fei Ai Za Zhi; 2007 Oct 20;10(5):391-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors for survival after lung cancer surgery in elderly patients].
  • BACKGROUND: With the improvement of the surgical and anesthetic techniques, there are increasing numbers of elderly surgical patients with lung cancer.
  • METHODS: Data were retrospectively analyzed from 192 patients aged ≥70 years who underwent lung cancer surgery.
  • Of these patients, 48.4% were in stage I, 20.8% in stage II, 19.3% in stage III, and 2.1% in stage IV.
  • Tumor characteristics: squamous cell carcinoma 49.0%, adenocarcinoma 35.9%, adenosquamous carcinoma 8.3%, small cell lung cancer 4.7%, others 2.1%.
  • Multivariable COX analysis demonstrated that incomplete resection (P=0.003), advanced surgical-pathological stage (P < 0.001) and other type of the tumor (P=0.016) were significant, independent, unfavorable prognostic determinants in patients.
  • CONCLUSIONS: Thoracic surgery is a safe and feasible approach in elderly patients with lung cancer.
  • Every effort should be made to detect early stage patients who might benefit from surgical treatment.
  • More limited lung surgery may be an adequate alternative in patients with associated co-morbidities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21126407.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Skúladóttir R, Oskarsdóttir GN, Isaksson HJ, Jónsson S, Thorsteinsson H, Gudbjartsson T: [Postoperative complications following lobectomy for lung cancer in Iceland during 1999-2008]. Laeknabladid; 2010 Apr;96(4):243-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative complications following lobectomy for lung cancer in Iceland during 1999-2008].
  • OBJECTIVE: Non small cell lung cancer (NSCLC) is the second most common cancer in Iceland.
  • Data on indications, histology, TNM-stage and complications were analysed, and logistic regression used to assess outcome predictors.
  • Adenocarcinoma (62%) and squamous cell carcinoma (29%) were the most frequent histological types.
  • Operative staging showed that 59.6% of cases were stage I, 17.8% were stage II, 7% were stage IIIA and 14.6% were stage IIIB or IV.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Outcome and Process Assessment (Health Care). Pneumonectomy / adverse effects. Postoperative Complications / etiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339163.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


5. Okamoto J, Onda M, Hirata T, Miyamoto S, Akaishi J, Mikami I, Hirai K, Haraguchi S, Koizumi K, Shimizu K: Dissimilarity in gene expression profiles of lung adenocarcinoma in Japanese men and women. Gend Med; 2006 Sep;3(3):223-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissimilarity in gene expression profiles of lung adenocarcinoma in Japanese men and women.
  • BACKGROUND: Although clinical differences in lung cancer between men and women have been noted, few studies have examined the sex dissimilarity using gene expression analysis.
  • OBJECTIVE: The purpose of this study was to determine the different molecular carcinogenic mechanisms involved in lung cancers in Japanese men and women.
  • METHODS: Patients who received surgery for stage I lung adenocarcinoma were included.
  • RESULTS: In a microarray analysis of tissue from 13 men and 6 women, 12 genes were under-expressed and 24 genes were overexpressed in lung adenocarcinoma in women compared with men.
  • CONCLUSION: Thirty-six genes that characterize lung adenocarcinoma by sex were selected.
  • This information may contribute to the development of novel diagnostic techniques and treatment modalities that consider sex differences in lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. RNA, Neoplasm / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081955.001).
  • [ISSN] 1550-8579
  • [Journal-full-title] Gender medicine
  • [ISO-abbreviation] Gend Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm
  •  go-up   go-down


6. Yang L, Lu QY, Wu MN, An TT, Zhao J, Guo QZ, Duan JC, Wang J: [A retrospective analysis: comparison of the clinical characteristics and prognosis in elderly and young patients with locally advanced or metastatic non-small cell lung cancer.]. Zhonghua Jie He He Hu Xi Za Zhi; 2009 Nov;32(11):830-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A retrospective analysis: comparison of the clinical characteristics and prognosis in elderly and young patients with locally advanced or metastatic non-small cell lung cancer.].
  • OBJECTIVE: To investigate whether the clinical characteristics, treatment modalities and prognosis of elderly (>/= 70 years) patients with advanced non-small cell lung cancer (NSCLC) differed from those of young (</= 45 years) patients.
  • (1) Women, adenocarcinoma and stage IV disease were more common in young patients (46.2% vs 22.3%, P = 0.000, 71.3% vs 54.7%, P = 0.001 and 72.7% vs 61.7%, P = 0.026), when compared with elderly patients.
  • CONCLUSION: Women, adenocarcinoma and stage IV disease were more common in young patients when compared with elderly patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung. Lung Neoplasms


7. Murthy SC, Reznik SI, Ogwudu UC, Farver CF, Arrossi A, Batizy LH, Nowicki ER, Mekhail TM, Mason DP, Rice TW, Blackstone EH: Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung. Ann Thorac Surg; 2010 Oct;90(4):1067-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung.
  • BACKGROUND: Understanding recurrence of surgically "cured" stage I adenocarcinoma of the lung is important given expected benefits of adjuvant therapy for advanced disease.
  • METHODS: From 1991 to 2001, 285 patients underwent resection of stage I adenocarcinoma (pathologic) of the lung.
  • CONCLUSIONS: Stage I adenocarcinoma of the lung recurs.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20868788.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Hirai K, Koizumi K, Haraguchi S, Hirata T, Mikami I, Fukushima M, Yamagishi S, Kawashima T, Okada D, Shimizu K, Kawamoto M: Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann Thorac Surg; 2005 Jan;79(1):248-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
  • This study was performed to elucidate the biologic significance of maspin expression in non-small cell lung cancer.
  • METHODS: To investigate whether maspin is involved in progression, clinicopathologic features, and prognosis of non-small cell lung cancer, we performed an immunohistochemical study using antimaspin antibody and identified the presence of maspin messenger ribonucleic acid in cancerous and noncancerous tissues by reverse transcription-polymerase chain reaction analysis.
  • RESULTS: Most adenocarcinoma and squamous cell carcinoma showed cytoplasmic staining pattern.
  • The cytoplasmic positive rate was 77.8% (42 of 54 specimens) for the stage III group, and 36.2% (21 of 58 specimens) for the stage I group (p < 0.0001).
  • In multivariate analysis, immunohistochemical maspin expression in patients with non-small cell lung cancer was an independent prognostic factor for overall survival.
  • There was an average fourfold increase in maspin messenger ribonucleic acid levels in cancerous tissues compared with those of noncancerous tissues, and stage III cases exhibited significantly higher maspin messenger ribonucleic acid levels than stage I cases (p = 0.003).
  • CONCLUSIONS: The results of this study suggest that overexpression of maspin in cytoplasm may be a useful marker of tumor progression and unfavorable prognosis for overall survival in some patients with non-small cell lung cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / chemistry. Lung Neoplasms / chemistry. Neoplasm Proteins / analysis. Serpins / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Aged. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / mortality. Cytoplasm / chemistry. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Genes, p53. Humans. Life Tables. Male. Middle Aged. Prognosis. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Survival Analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620951.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


9. Sun Z, Wigle DA, Yang P: Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol; 2008 Feb 20;26(6):877-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival.
  • PURPOSE: Gene expression profiling for outcome prediction of non-small-cell lung cancer (NSCLC) remains clouded by heterogeneous and unvalidated results.
  • MATERIALS AND METHODS: Two NSCLC oligonucleotide microarray data sets of adenocarcinoma and squamous cell carcinoma were used as training sets to select prognostic genes independent of conventional predictors.
  • RESULTS: Adenocarcinomas with the 50-gene signature from adenocarcinoma in both validation data sets had a 2.4-fold (95% CI, 1.3 to 4.4 and 1.0 to 5.8) increased mortality after adjustment for conventional predictors.
  • Squamous cell carcinoma with this high-risk signature had an adjusted risk of 1.1 (95% CI, 0.4 to 3.2) in one data set and 2.5 (95% CI, 1.1 to 5.8) in another consisting of stage I tumors.
  • Adenocarcinoma with the 50-gene signature from squamous cell carcinoma had an elevated risk of 3.5 (95% CI, 1.4 to 9.0) after adjustment for conventional predictors.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / mortality. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / mortality. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Proportional Hazards Models. ROC Curve. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281660.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA115857; United States / NCI NIH HHS / CA / CA80127; United States / NCI NIH HHS / CA / CA84354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL: KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res; 2007 Jun 01;13(11):3229-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer.
  • PURPOSE: The mitotic kinesin KIF14 is overexpressed in multiple cancers including lung cancer.
  • Therefore, we investigated KIF14 expression in association with clinical variables and the effect of KIF14 on in vitro colony formation in non-small-cell lung carcinoma.
  • RESULTS: Squamous cell carcinoma had the highest KIF14 level, followed by large-cell undifferentiated carcinoma, then adenocarcinoma (P = 0.002).
  • KIF14 level decreased with differentiation (P = 0.01) but was not associated with pathologic stage, T or N stage, or sex.
  • In a multivariate Cox regression, including stage, differentiation, histology, and tumor purity as covariates, KIF14 overexpression remained an independent prognostic factor for disease-free survival [P = 0.01; hazard ratio, 1.45 (95% confidence interval, 1.09-1.94)].
  • Knockdown of KIF14 in non-small-cell lung carcinoma and cervical carcinoma cell lines decreased proliferation and colony formation in soft agar.
  • CONCLUSIONS: KIF14 expression is independently prognostic for disease-free survival in lung cancer and knockdown decreases tumorigenicity in vitro, showing that it is a clinically relevant oncogene and an exciting therapeutic target for further study.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Kinesin / genetics. Kinesin / physiology. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Oncogene Proteins / genetics. Oncogene Proteins / physiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545527.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118830; United States / NCI NIH HHS / CA / R01 CA118830-04
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins; 0 / RNA, Small Interfering; EC 3.6.1.- / KIF14 protein, human; EC 3.6.4.4 / Kinesin
  •  go-up   go-down


11. Kobayashi N, Toyooka S, Ichimura K, Soh J, Yamamoto H, Matsuo K, Otani H, Jida M, Kubo T, Tsukuda K, Kiura K, Sano Y, Date H: Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. J Thorac Oncol; 2008 Jul;3(7):704-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung.
  • OBJECTIVE: The purpose of this study was to identify risk factors for poor clinical outcome after surgical resection of small lung adenocarcinoma.
  • MATERIALS AND METHODS: Clinical records of 127 patients who had pathologic stage IA lung adenocarcinoma 20 mm or less and who had undergone a lobectomy with mediastinal lymph node dissection were reviewed.
  • CONCLUSION: The high non-BAC component but not EGFR mutation status, is an independent risk factor for both recurrence and poor prognosis in patients with stage IA lung adenocarcinoma <or=20 mm.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Genes, erbB-1 / genetics. Lung Neoplasms / pathology. Mutation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18594314.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Ilic N, Petricevic A, Arar D, Kotarac S, Banovic J, Ilic NF, Tripkovic A, Grandic L: Skip mediastinal nodal metastases in the IIIa/N2 non-small cell lung cancer. J Thorac Oncol; 2007 Nov;2(11):1018-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skip mediastinal nodal metastases in the IIIa/N2 non-small cell lung cancer.
  • INTRODUCTION: To study the incidence and characteristics of mediastinal nodal metastases without N1 nodal metastases (skip N2 metastases) in patients with resected pIII/A/N2 non-small cell lung cancer.
  • METHODS: A total of 323 non-small cell lung cancer patients who underwent radical surgical resection with a systematic mediastinal nodal dissection in 4-year period (2000-2003) were retrospectively reviewed.
  • The 85 patients (26%) at stage IIIA/N2 (pN2+) were grouped according to their skip metastases status.
  • The incidence of N2 metastases seemed to be more frequent in adenocarcinoma patients (p < 0.005), but skip N2 metastases were significantly higher (p < 0.001) in squamous cell carcinoma patients.
  • CONCLUSIONS: Sample mediastinal lymphadenectomy may not be appropriate in surgery for non-small cell lung cancer because skip metastases were found in 25% of patients without N1 nodal involvement.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Mediastinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975493.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG: Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis; 2008 May;29(5):895-904
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung.
  • BACKGROUND: Atypical adenomatous hyperplasia (AAH) is now recognized as a precursor lesion from which lung adenocarcinomas arise and thus represents an ideal target for studying the early genetic and epigenetic alterations associated with lung tumorigenesis such as alterations of the Wnt pathway.
  • METHODS: We assessed the level of Wnt signaling activity in lung cancer cell lines by determining the level of active beta-catenin and determined the level of expression of Wnt antagonists APC, DKK1, DKK3, LKB1, SFRP1, 2, 4, 5, WIF1 and RUNX3 using reverse transcription-polymerase chain reaction.
  • Using multiplex nested methylation-specific polymerase chain reaction, we analyzed promoter region methylation of these genes in resected lung tissue in the histopathologic sequence of glandular neoplasia (normal lung parenchyma, low-grade and high-grade AAH, adenocarcinoma).
  • RESULTS: The majority of non-small cell lung cancer cell lines (11 of 16, 69%) have evidence of active Wnt signaling and silencing of Wnt antagonists correlated with promoter hypermethylation.
  • Promoter region methylation of Wnt antagonists was common in primary lung adenocarcinoma and there was a significant increase in the frequency of methylation for Wnt antagonist genes and the number of genes methylated with each stage of tumorigenesis (test for rend P <or= 0.01).
  • CONCLUSION: These results show that gene silencing of Wnt antagonists by promoter hypermethylation occurs during the earliest stages of glandular neoplasia of the lung and accumulates with progression toward malignancy.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] Lung Cancer. 2007 Apr;56(1):35-42 [17241687.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):316-21 [11170292.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4249-57 [11464291.001]
  • [Cites] Respir Res. 2000;1(3):163-9 [11667981.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Hum Mol Genet. 2001 Dec 15;10(26):3001-7 [11751682.001]
  • [Cites] EMBO Rep. 2002 Jan;3(1):63-8 [11751573.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):552-6 [11932749.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4519-24 [12154064.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3133-7 [12810640.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2998-3003 [12912948.001]
  • [Cites] Nat Cell Biol. 2003 Oct;5(10):889-94 [12973359.001]
  • [Cites] Pathol Int. 2003 Dec;53(12):823-7 [14629747.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Cancer Lett. 2004 Apr 30;207(2):197-203 [15072829.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Arch Pathol Lab Med. 1990 Apr;114(4):363-8 [2322096.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3164-73 [1591728.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):876-87 [7717455.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):553-62 [8619420.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):801-8 [9712420.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4584-94 [15542810.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Mol Genet Genomics. 2005 Apr;273(2):184-96 [15731909.001]
  • [Cites] Semin Roentgenol. 2005 Apr;40(2):90-7 [15898407.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1907-18 [15940626.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6323-7 [16007200.001]
  • [Cites] Mol Genet Genomics. 2005 Sep;274(2):141-54 [16049682.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]
  • [Cites] Oncol Rep. 2006 Jan;15(1):129-35 [16328045.001]
  • [Cites] Chest. 2000 Apr;117(4 Suppl 1):80S-89S [10777460.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):83-96 [16219426.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1371-5 [16452191.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):761-3 [16481647.001]
  • [Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]
  • [Cites] PLoS One. 2006;1:e93 [17183725.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):3-14 [17311529.001]
  • [Cites] Lung Cancer. 2000 Nov;30(2):73-81 [11086200.001]
  • (PMID = 18308762.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058184
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / DMAP1 protein, human; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 0 / Wnt Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC3312609
  •  go-up   go-down


14. Ozkok S, Karakoyun-Celik O, Goksel T, Mogulkoc N, Yalman D, Gok G, Bolukbasi Y: High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients. Lung Cancer; 2008 Dec;62(3):326-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients.
  • The aim of this study was to evaluate the symptomatic and endoscopic responses as well as the toxicities in 158 patients with endobronchial lung cancer treated with high dose rate endobronchial brachytherapy (HDR-EB).
  • Forty-three patients with stage III NSCLC were treated with 60Gy external beam radiotherapy (ERT) and three applications of 5Gy each of HDR-EB (group A).
  • HDR-EB provides effective palliation in relieving the symptoms of patients with endobronchial lung cancer, however, there is a risk of developing FH that is associated with a high BED and multiple HDR-EB applications.
  • [MeSH-major] Brachytherapy. Bronchial Neoplasms / radiotherapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Bronchoscopy. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Palliative Care. Prognosis. Prospective Studies. Radiation Tolerance. Radiotherapy Dosage. Small Cell Lung Carcinoma / pathology. Small Cell Lung Carcinoma / radiotherapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482780.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


15. Guo L, Ma Y, Ward R, Castranova V, Shi X, Qian Y: Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3344-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma.
  • PURPOSE: Individualized therapy of lung adenocarcinoma depends on the accurate classification of patients into subgroups of poor and good prognosis, which reflects a different probability of disease recurrence and survival following therapy.
  • All patients in cluster 1 were in stage I, with N0 lymph node status (no metastasis) and smaller tumor size (T1 or T2).
  • Additionally, a 12-gene signature correctly predicts the stage of 94.2% of patients.
  • CONCLUSIONS: Our results show that the prediction models based on the expression levels of a small number of marker genes could accurately predict patient outcome for individualized therapy of lung adenocarcinoma.
  • Such an individualized treatment may significantly increase survival due to the optimization of treatment procedures and improve lung cancer survival every year through the 5-year checkpoint.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740756.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA119028-01; United States / NCRR NIH HHS / RR / P20 RR16440-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


16. Clément-Duchêne C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA: A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol; 2010 Nov;5(11):1821-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
  • BACKGROUND: Bevacizumab improves responses and progression-free survival when added to first-line paclitaxel/carboplatin or cisplatin/gemcitabine for patients with advanced nonsquamous non-small cell lung cancer.
  • METHODS: Patients with untreated advanced nonsquamous non-small cell lung cancer, with no evidence of brain metastases and not on anticoagulation were eligible.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3284-9 [19433684.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3217-24 [19433683.001]
  • [Cites] Future Oncol. 2009 Dec;5(10):1545-53 [20001795.001]
  • [Cites] Ann Oncol. 2010 Sep;21(9):1804-9 [20150572.001]
  • [Cites] Lung Cancer. 2010 Dec;70(3):340-6 [20347506.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 9):50-4 [12094340.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):242-7 [12562651.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):243-8 [8664035.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):69-80 [15603856.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):142-53 [15625369.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8380-8 [16293868.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Thorac Oncol. 2008 May;3(5):511-5 [18449004.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):689-99 [18471042.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4617-25 [18678835.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20881641.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA124435; United States / NCRR NIH HHS / RR / UL1 RR025744; United States / NCATS NIH HHS / TR / UL1 TR001085
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS637070; NLM/ PMC4241413
  •  go-up   go-down


17. Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, Uliano M: The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma. Lung Cancer; 2010 Aug;69(2):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.
  • The SUVmax values resulted significantly related to histological subtypes (p<0.001), histological grading (p<0.001), and pathologic stage (p<0.001).
  • SUVmax still remain a significant predictor of survival in Stage IB (2-year DSS of 100% for SUVmax < or =6.7; 51% for SUVmax >6.7, p=0.016).
  • The optimal cut-off values of SUVmax to predict prognosis were 5 for adenocarcinoma (p=0.027) and 10.7 for other non-adenocarcinoma NSCLC subtypes (p=0.010).
  • These histologic-specific cut-offs resulted significantly related to survival when stratified for stage: 2-year DSS for Stage IB adenocarcinoma were 100% for SUV< or =5 and 40% for SUVmax >5 (p=0.051); 2-year DSS for Stage IB non-adenocarcinoma were 83% for SUVmax < or =10.7 and 26% for SUVmax >10.7 (p=0.018).
  • In conclusion, SUVmax represents a significant prognostic factor in surgically resected NSCLC but a great variability between different histological subtypes, even when adjusted for stage, is present and could be considered when planning future trials on prognostic role of FDG uptake.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Fluorodeoxyglucose F18 / pharmacokinetics. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19942313.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Zheng H, Wang J, Meng Q, Liu Z, Li B, Zhu Y: [Target therapy of gefitinib in advanced adenocarcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):229-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Target therapy of gefitinib in advanced adenocarcinoma of the lung].
  • BACKGROUND: Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which is used to treat advanced non-small cell lung cancer, especially adenocarcinoma.
  • The aim of this study is to evaluate the efficacy, side effects and prognostic factors of gefitinib in adenocarcinoma of the lung.
  • METHODS: A total of 26 patients with advanced adenocarcinoma of the lung were enrolled in the study.
  • Age ( < 70 years old), skin rash and CEA decrease were significantly related to longer survival, however, times of prior chemotherapy and gefitinib treatment stage did not influence the survival.
  • It can significantly improve quality of life of patients with adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118653.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Leinonen T, Pirinen R, Böhm J, Johansson R, Kosma VM: Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol; 2008 06;23(6):693-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer.
  • The purpose of this study was to analyse the expression of matrix metalloproteinase-2 (MMP-2) and its extracellular matrix metalloproteinase inducer (EMMPRIN) in non-small cell lung cancer (NSCLC), and to evaluate their significance to predict tumour behaviour.
  • In overall survival (OS) and disease free survival (DFS) analyses, type of tumour (p=0.001 and p=0.0004), advanced stage (p=0.001 and p=0.013) and high MMP-2 expression in tumour cells (p=0.018 and p=0.001) were associated with poor survival.
  • In multivariate analysis, stromal MMP-2 expression retained its prognostic value to predict OS and DFS (p=0.028 and p=0.039, respectively), together with tumour type and stage (p=0.017, p=0.001 and p=0.021, p=0.008, respectively).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Matrix Metalloproteinase 2 / metabolism. Neoplasm Recurrence, Local
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adult. Aged. Antigens, CD147 / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Large Cell / enzymology. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Disease-Free Survival. Finland / epidemiology. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366007.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 136894-56-9 / Antigens, CD147; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


20. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE: Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol; 2008 Sep;3(9):1003-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
  • INTRODUCTION: This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib administered with two standard chemoradiotherapy regimens for non-small cell lung cancer.
  • METHODS: Unresectable stage III non-small cell lung cancer patients were enrolled in this 2-arm dose-escalation study.
  • Erlotinib, given only during chemoradiotherapy, was escalated from 50 to 150 mg/d in 3 to 6 patient cohorts.
  • PATIENT CHARACTERISTICS: performance status 0 to 24 patients, 1 to 10 patients, median age 63 years, adenocarcinoma 21% and female 14 patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758303.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009566-15; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / P30 CA14599-32; United States / NCI NIH HHS / CA / CA009566-15; United States / NCI NIH HHS / CM / N01 CM007003; United States / NCI NIH HHS / CM / N01 CM-07003-74; United States / NCI NIH HHS / CA / T32 CA009566
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS154299; NLM/ PMC4535721
  •  go-up   go-down


21. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S, Stuerzbecher HW: High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer; 2005 Jul 11;93(1):137-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients.
  • This study was aimed to evaluate Rad51 expression to serve as prognostic marker in non-small-cell lung cancer (NSCLC).
  • A total of 383 non-small-cell lung tumours were analysed immunohistochemically on NSCLC tissue microarrays.
  • Similarly T status, N status, M status, clinical stage and histological tumour grade were significant prognostic markers in univariate Cox survival analysis.
  • Importantly, Rad51 expression (P<0.0001) together with tumour differentiation (P<0.009), clinical stage (P=0.004) and N status (P=0.0001) proved to be independent prognostic parameters in multivariate analysis.
  • Rad51 expression predicted the outcome of squamous cell cancer as well as adenocarcinoma of the lung.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. DNA-Binding Proteins / metabolism. Lung Neoplasms / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Jan 1;62(1):219-25 [11782381.001]
  • [Cites] Nucleic Acids Res. 1998 Jun 15;26(12):2859-64 [9611228.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]
  • [Cites] Chest. 2002 Sep;122(3):1037-57 [12226051.001]
  • [Cites] Surg Oncol. 2002 Dec;11(4):181-90 [12450554.001]
  • [Cites] Toxicology. 2003 Nov 15;193(1-2):91-109 [14599770.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):800-5 [9743304.001]
  • [Cites] Oral Oncol. 1998 Nov;34(6):524-8 [9930366.001]
  • [Cites] Oncogene. 2000 May 25;19(23):2791-5 [10851081.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):907-13 [11093813.001]
  • [Cites] Cancer Detect Prev. 1982;5(4):391-406 [6303590.001]
  • [Cites] Eur Respir J. 1994 Jul;7(7):1350-64 [7925916.001]
  • [Cites] EMBO J. 1996 Apr 15;15(8):1992-2002 [8617246.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6236-40 [8692798.001]
  • [Cites] Hybridoma. 1996 Jun;15(3):205-10 [8823618.001]
  • [Cites] Cell. 1997 Jan 24;88(2):265-75 [9008167.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):804-10 [9126738.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7151-8 [9372947.001]
  • [Cites] EMBO J. 1998 Jan 15;17(2):598-608 [9430650.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Apr 17;245(2):319-24 [9571148.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):126-8 [11784881.001]
  • (PMID = 15956972.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.- / RAD51 protein, human; EC 2.7.7.- / Rad51 Recombinase
  • [Other-IDs] NLM/ PMC2361489
  •  go-up   go-down


22. Kim DS, Kim MJ, Lee JY, Lee SM, Choi JY, Yoon GS, Na YK, Hong HS, Kim SG, Choi JE, Lee SY, Park JY: Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features. Mol Carcinog; 2009 Dec;48(12):1109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
  • Homeobox A5 (HOXA5) is a master regulator of the morphogenesis and cell differentiation to be implicated as a tumor suppressor gene in breast cancer, but its role in lung cancer is still unknown.
  • In this study, we have investigated the methylation status of the promoter region of the HOXA5 gene in nonsmall cell lung cancers (NSCLCs) using nested and standard methylation-specific PCR (MSP) and correlated the methylation status with clinicopathological features.
  • With standard MSP analysis, HOXA5 methylation were found in 113 (81.3%) of 139 NSCLCs and 72 (51.8%) in their corresponding nonmalignant lung tissues.
  • Moreover, in the patients with stage I disease, HOXA5 methylation was more frequent in smokers than in never-smokes (P = 0.01).
  • However, in the patients with stage I disease, HOXA5 methylation was associated with a borderline significantly worse survival (P = 0.09).
  • Additional studies with larger sample sizes are required to evaluate the prognostic value of HOXA5 methylation in patients with stage I NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Lung Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554572.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXA5 protein, human; 0 / Homeodomain Proteins; 0 / RNA, Messenger
  •  go-up   go-down


23. Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA, Santoro A: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol; 2010 Mar;21(3):562-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.
  • BACKGROUND: The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC).
  • Patient characteristics and methods: This retrospective study was conducted in 369 stage I-II-IIIA, surgically resected, NSCLC patients.
  • No difference in survival was observed between IGF1R-positive and -negative patients in a subgroup of stage I-II adenocarcinoma (n = 137) with known EGFR mutation and copy number status.


24. Rena O, Carsana L, Cristina S, Papalia E, Massera F, Errico L, Bozzola C, Casadio C: Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardiothorac Surg; 2007 Dec;32(6):863-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance.
  • OBJECTIVE: To determine the prevalence and prognostic significance of lymph node micrometastases and isolated tumor cells (ITC) in patients submitted for radical resection for pathological stage I non-small cell lung cancer (NSCLC).
  • Surgical specimens were submitted to pathological routine examinations to define histotype, grade, stage, vascular invasion, necrosis and tumor proliferative index.
  • RESULTS: By histological examination, there were 36 squamous-cell carcinoma, 38 adenocarcinoma and 13 large-cell carcinoma.
  • Significant correlation was observed between micrometastases or ITC and adenocarcinoma (p=0.03) and the absence of necrosis (p=0.05).
  • DISCUSSION: Micrometastases or ITC to regional lymph nodes are demonstrated to be not a rare aspect of pathological stage I resected lung cancer.
  • In our series, the presence of lymph nodes micrometastases does not affect long-term disease-free survival.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology


25. Chen PC, Zhou XM, Chen QX, Liu JS, Yan FL, Jiang YH: [Sleeve resection for lung cancer: a report of 82 cases]. Ai Zheng; 2008 May;27(5):510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sleeve resection for lung cancer: a report of 82 cases].
  • BACKGROUND & OBJECTIVE: Bronchial sleeve resection and/or pulmovascular sleeve resection can maximize preservation of normal lung tissues after tumor resection, which provides a resection mode for lung cancer surgery.
  • This study was to investigate the technique, operative results and survival of lung cancer patients after sleeve resection.
  • METHODS: Eighty-two central lung cancer patients underwent sleeve resection in Zhejiang Cancer Hospital from Jun.
  • Of the 82 patients, 49 (59.8%) were at stage N1, 21 (25.6%) at stage N2.
  • CONCLUSIONS: Perioperative mortality and the incidence of anastomosis-related complications for lung cancer patients after sleeve resection are low.
  • The survival of lung cancer patients after sleeve resection is conelated to lymph node metastasis and clinical stage, but has no correlation to gender or age.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Lymph Node Excision / methods. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Survival Rate


26. Lu P, Yu L, Li Y, Sun Y: A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer. Nucl Med Commun; 2010 Jul;31(7):646-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer.
  • OBJECTIVE: To investigate the relationship between maximum standardized uptake value and pathological type, degree of differentiation, tumor size, and clinical staging of nonsmall cell lung cancer (NSCLC).
  • RESULTS: There was a significant correlation between the SUVmax of NSCLC and the pathological type (r= 0.391, P= 0.000); the SUVmax of squamous cell carcinoma (SCC) was higher than that of adenocarcinoma (AC) (P =0.000), and the SUVmax of AC was higher than that of bronchioloalveolar carcinoma (P = 0.004).
  • The SUVmax of AC had a positive correlation with clinical staging (r= 0.298, P = 0.006); SUVmax was lower in stage I than in stages II, III, and IV (P = 0.047, 0.038 and 0.015, respectively); however, the SUVmax in stages II, III, and IV were not different (P= 0.708, 0.570 and 0.528, respectively).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Biological Transport. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tumor Burden

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wolters Kluwer Health / Lippincott Williams & Wilkins.
  • (PMID = 20545045.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


27. Chen KY, Chang CH, Yu CJ, Kuo SH, Yang PC: Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma. Cancer; 2005 Jun 15;103(12):2566-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma.
  • BACKGROUND: The results from previous studies suggested that the clinical characteristics and outcomes of patients with lung carcinoma vary between gender and age groups.
  • The objective of the current study was to assess the trend in the evolution of the histologic types in Taiwan and to compare the outcomes of patients with lung carcinoma between different gender and age groups.
  • METHODS: Patients with primary lung carcinoma were identified through the cancer registry system.
  • Clinical records were reviewed and analyzed for age, gender, disease stage, histology, treatment modalities, and survival.
  • A multivariate analysis using a Cox proportional hazards model was applied for gender, age (by decade), histologic type, disease stage, and treatment modality.
  • RESULTS: Between 1991-1999, 2714 patients with histologically or cytologically proven lung carcinoma were included.
  • Adenocarcinoma was the major cell type of lung carcinoma (52.5%), with a significant trend toward an increase in adenocarcinoma during the study period.
  • A significantly high percentage of adenocarcinoma was demonstrated in female patients (73.5%), who also had better survival compared with male patients (P = 0.002), especially in the group age 50-69 years.
  • Patients age < 40 years also had a poor prognosis, which was worse compared with the prognosis for patients age 40-59 years. patients who had adenocarcinoma had a better survival rate compared with patients who had other histologic types (relative risk, 0.78; 95% confidence interval, 0.69-0.87).
  • CONCLUSIONS: Adenocarcinoma was predominant in female patients and emerged as a greater problem than other histologic types in Taiwan, potentially raising the importance of studies regarding the benefit of population diversity in new antitumor therapies, such as gefitinib.
  • Female patients with lung carcinoma had a better prognosis than male patients in the group age 50-69 years, warranting further studies on potential prognostic factors associated with middle age, such as hormone status.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Sex Distribution. Survival Rate. Taiwan. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15852359.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan V, Dowlati A, Shi X, Castranova V, Beer DG, Qian Y: Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res; 2008 Dec 15;14(24):8213-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confirmation of gene expression-based prediction of survival in non-small cell lung cancer.
  • PURPOSE: It is a critical challenge to determine the risk of recurrence in early stage non-small cell lung cancer (NSCLC) patients.
  • EXPERIMENTAL DESIGN: Multiple published microarray data sets were used to evaluate our previously identified lung cancer prognostic gene signature.
  • Expression of the signature genes was further validated with real-time reverse transcription-PCR and Western blot assays of snap-frozen lung cancer tumor tissues.
  • The 35-gene signature further stratified patients with clinical stage 1A diseases into poor prognostic and good prognostic subgroups (P = 0.0007, Kaplan-Meier analysis, log-rank tests).
  • This signature is independent of other prognostic factors for NSCLC, including age, sex, tumor differentiation, tumor grade, and tumor stage.
  • The expression of the signature genes was validated with real-time reverse transcription-PCR analysis of lung cancer tumor specimens.
  • Protein expression of two signature genes, TAL2 and ILF3, was confirmed in lung adenocarcinoma tumors by using Western blot analysis.
  • These two biomarkers showed correlated mRNA and protein overexpression in lung cancer development and progression.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2000 Oct 20;80(2):192-202 [11074587.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):26-31 [11227069.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3005-8 [12036904.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Genome Biol. 2003;4(4):R27 [12702208.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Aug;29(2):157-62 [12600827.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Oncogene. 2004 Jul 8;23(31):5360-70 [15064725.001]
  • [Cites] Science. 2004 Oct 22;306(5696):640-3 [15499008.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3875-84 [15492012.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7278-85 [16129846.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Science. 2006 May 26;312(5777):1165-8 [16728629.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3344-54 [16740756.001]
  • [Cites] Exp Oncol. 2006 Jun;28(2):99-105 [16837898.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Mamm Genome. 2006 Sep;17(9):941-9 [16964442.001]
  • [Cites] Breast Cancer Res Treat. 2006 Nov;100(2):229-35 [16932852.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5079-90 [17075127.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] BMC Bioinformatics. 2007;8 Suppl 1:S5 [17430572.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2946-54 [17504995.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • (PMID = 19088038.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084953-050003; United States / NCRR NIH HHS / RR / P20 RR016440; United States / NCRR NIH HHS / RR / P20 RR16440-03; United States / NCI NIH HHS / CA / R01 CA060731; United States / NCI NIH HHS / CA / 5R01CA060731-13; United States / NLM NIH HHS / LM / R01 LM009500; United States / NLM NIH HHS / LM / LM009500-01A2; United States / NCI NIH HHS / CA / U19 CA084953-050003; United States / NCRR NIH HHS / RR / RR016440-08; United States / NLM NIH HHS / LM / R01 LM009500-01A2; United States / NCRR NIH HHS / RR / P20 RR016440-08; United States / NCI NIH HHS / CA / U19 CA084953; United States / NCI NIH HHS / CA / R01 CA154365
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS78586; NLM/ PMC2605664
  •  go-up   go-down


29. Jin X, Zhang J, Gao Y, Ding K, Wang N, Zhou D, Jen J, Cheng S: Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer. Mitochondrion; 2007 Sep;7(5):347-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer.
  • To investigate the possible role of mtDNA mutations in lung cancer, we sequenced complete mtDNA of lung cancer tissues, corresponding normal (i.e., non-cancerous) lung tissues, and peripheral blood samples from 55 lung cancer patients and examined the relationship between mtDNA mutations or polymorphisms and clinical parameters.
  • There was no association of incidence of specific mtDNA mutation or polymorphism with patients' gender, age at diagnosis, smoking history, tumor type or tumor stage (P>0.05).
  • This study revealed a variety of mtDNA mutations and mtDNA polymorphisms in human lung cancer, some of which might be involved in human lung carcinogenesis.
  • [MeSH-major] DNA, Mitochondrial / genetics. Lung Neoplasms / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adenocarcinoma / genetics. Aged. Carcinoma, Adenosquamous / genetics. Carcinoma, Small Cell / genetics. Carcinoma, Squamous Cell / genetics. Female. Humans. Male. Middle Aged. Point Mutation

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707697.001).
  • [ISSN] 1567-7249
  • [Journal-full-title] Mitochondrion
  • [ISO-abbreviation] Mitochondrion
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


30. Chen QY, Jiang ZY, Wu LJ, Zhang BY, Lu GH, Zhou JY: [Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):278-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma].
  • OBJECTIVE: To detect the expression of alpha-tubulin and MDR1 in human non-small cell lung carcinoma (NSCLC), and to clarify their clinical significance.
  • METHODS: Paraffin embedded tissues from 158 primary non-small lung carcinomas and 30 paracancerous lung tissues were examined for expression of alpha-tubulin and MDR1 by immunohistochemistry (SP method).
  • The relationship between alpha-tubulin and MDR1 expression and the biological features of lung carcinoma was analyzed.
  • RESULTS: The positive rate of alpha-tubulin and MDR1 expressions in the lung carcinomas was 65.2% and 51.3%, respectively.
  • There was no expression of either of them in 30 paracancerous lung tissues.
  • The positive rate of alpha-tubulin expression was gradually increased with tumor progression, significantly higher in III-IV stage cancers and in poorly differentiated carcinomas (both P < 0.01).
  • There was a distinct statistically significant difference between stage I, stage II and III, and stage IV.
  • But the positive rate of MDR1 in adenocarcinoma was significantly higher than that in squamous carcinoma and undifferentiated large cell carcinomas (P < 0.01).
  • Univariate analysis showed that the 5-year survival rate of patients with negative alpha-tubulin and MDR1 expression was 30.7% and 28.5%, respectively, significantly higher than that of patients with positive alpha-tubulin and MDR1 expression (13.5% and 11.8%, respectively) (chi(2) = 20.69 and 15.52, P < 0.01, respectively), and multivariate Cox regression analysis showed that alpha-tubulin (RR = 3.287, P = 0.006) and clinical TNM stage (RR = 1.954, P = 0.025) were significantly independent predictive factor for patients with lung cancer, MDR1 and other factors could not be used as an independent predicitive factors.
  • However, there was no significant correlation between the expression of alpha-tubulin and MDR1 in lung carcinoma(r = 0.093, P > 0.05).
  • CONCLUSION: The expression of alpha-tubulin and MDR1 may play an important role in the development and progression of human non-small cell lung carcinoma.
  • Combined detection could be considered as an important index for predicting prognosis of lung carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. P-Glycoprotein / metabolism. Tubulin / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. P-Glycoproteins. Paraffin Embedding. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510079.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / TUBA1A protein, human; 0 / Tubulin
  •  go-up   go-down


31. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol; 2006 Jan 7;12(1):54-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues.
  • Statistical analysis between clinicopathological factors and subcellular localization of KL-6 mucin showed that KL-6 localization in the circumferential membrane and/or cytoplasm was significantly associated with the presence of venous invasion (P = 0.0003), lymphatic invasion (P<0.0001), lymph node metastasis (P<0.0001), liver metastasis (P = 0.058), and advanced histological stage (P<0.0001).
  • CONCLUSION: The subcellular staining pattern of KL-6 in colorectal adenocarcinoma may be an important indicator for unfavorable behaviors such as lymph node and liver metastasis, as well as for the prognosis of patients.
  • [MeSH-major] Adenocarcinoma / chemistry. Antigens / analysis. Colorectal Neoplasms / chemistry. Glycoproteins / analysis. Mucins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1988 Mar 25;263(9):4215-22 [3346246.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5450-4 [16222735.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):455-9 [10675475.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L625-9 [10710536.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):425-30 [11819805.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1183-90 [12054500.001]
  • [Cites] Histopathology. 2003 Mar;42(3):239-45 [12605643.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5011-20 [12941828.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):3044-7 [15378790.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):223-32 [6094338.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1113-23 [2045853.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2318-24 [1559234.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2563-8 [1373671.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2191-9 [8384065.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):255-65 [7698991.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):171-6 [8667623.001]
  • [Cites] Nat Med. 1998 Jan;4(1):43-9 [9427605.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):307-19 [9663420.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1262-72 [9788390.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):67-71 [15782996.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):203-16 [3411786.001]
  • (PMID = 16440417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  • [Other-IDs] NLM/ PMC4077483
  •  go-up   go-down


32. Petrovic M, Tomic I, Plavec G, Ilic S, Ilic N, Baskic D: Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. J BUON; 2008 Jan-Mar;13(1):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer.
  • PURPOSE: To determine the frequency of neuron specific enolase (NSE) tissue expression and its possible influence on survival of patients treated for advanced non small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: We studied 158 patients with histological diagnosis of NSCLC (stage III/IV).
  • Combined chemoradiotherapy was used in stage III disease (without pleural effusion), whereas chemotherapy only was used in stage III (with pleural effusion) as well as in stage IV disease.
  • The most frequent NSE expression was seen in 6/9 (66.7%) patients with large cell carcinoma and in 23/50 (46%) with adenocarcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Phosphopyruvate Hydratase / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404793.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


33. Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B: Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch; 2006 Jul;449(1):31-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the up-regulated expression of HLA-G in MM effusions and its possible association with shorter disease-free survival in advanced stage of breast carcinoma suggest a possible role in immune response evasion in some tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis. Mesothelioma / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):914-20 [12131159.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Acta Cytol. 1994 Nov-Dec;38(6):945-52 [7992584.001]
  • [Cites] Blood. 2002 Jan 15;99(2):609-17 [11781245.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1515-23 [12438449.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):18-25 [11836665.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(2):119-28 [14997042.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1954-60 [10213506.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):5922-8 [9637505.001]
  • [Cites] Respiration. 1998;65(2):108-13 [9580921.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6838-45 [11559559.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):243-50 [14639610.001]
  • [Cites] Eur J Surg Oncol. 1994 Feb;20(1):33-6 [8131866.001]
  • [Cites] Hum Immunol. 2005 Feb;66(2):164-9 [15695002.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1081-92 [14602239.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):512-8 [10225437.001]
  • [Cites] J Immunol Methods. 2002 Jun 1;264(1-2):109-19 [12191515.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):246-54 [15452897.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):42-7 [15589578.001]
  • [Cites] Clin Lab Med. 2003 Sep;23(3):729-54, viii [14560537.001]
  • [Cites] Microbes Infect. 2002 Dec;4(15):1539-44 [12505526.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):904-10 [15069585.001]
  • [Cites] Lung Cancer. 2004 May;44(2):159-65 [15084380.001]
  • [Cites] Semin Oncol. 1985 Mar;12(1):54-75 [2579439.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7335-46 [15534110.001]
  • [Cites] Placenta. 2000 Mar-Apr;21 Suppl A:S86-92 [10831130.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):43-9 [10431845.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7167-75 [14612510.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1177-95 [11137224.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4107-11 [12874014.001]
  • [Cites] Clin Exp Metastasis. 2004;21(5):469-76 [15672872.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23 ):5490-8 [8968106.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1377-87 [8620412.001]
  • [Cites] Hum Immunol. 2002 Nov;63(11):969-76 [12392849.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):317-23 [14708711.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1405-12 [11684957.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3771-8 [7706718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):85-92 [12109861.001]
  • (PMID = 16541284.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I; 0 / RNA, Messenger
  •  go-up   go-down


34. Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J, Treska V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res; 2009 Jul;29(7):2513-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
  • The expression of matrix metallo-proteinases (MMP-7 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2), which are involved in the degradation of the extracellular matrix (ECM) and tumor growth, was investigated in normal lung tissue, tissue of benign pulmonary diseases and non-small cell lung cancer (NSCLC) tissue.
  • PATIENTS AND METHODS: Tumor tissue and surrounding carcinoma-free lung tissue samples were obtained from 91 patients with NSCLC who had undergone surgery in the years 2005-2007 as well as lung tissue from 12 patients operated on for 'benign' bullous emphysema or interstitial lung disease.
  • RESULTS: Significantly higher expression of MMP-7, MMP-9 and TIMP-1 mRNA was demonstrated in the NSCLC tissue in comparison with the normal lung tissue from the same patients (p=0.0003, p<0.0001 and p=0.0018, respectively).
  • Similar results for MMP-7, MMP-9 and TIMP-1 were found in the histological subgroups: squamous cell lung cancer vs. normal tissue (p=0.0198, p=0.0015 and p=0.0366, respectively), and adenocarcinoma vs. normal tissue (p=0.0045, p<0.0001 and p=0.0140, respectively).
  • The expression of MMP-7 was found to be significantly higher in tumor tissue vs. lung tissue of the benign diseases (p=0.0086) and similar results were also recorded in the histological subgroups: squamous cell lung cancer vs. benign tissue (p=0.0171) and adenocarcinoma vs. benign tissue (p=0.0135).
  • The expression of MMP-9 was significantly higher only in the adenocarcinoma subgroup vs. the benign tissue (p=0.0412).
  • No differences in the expression of mRNA between stage IA and stages IB-IIIB of NSCLC were recorded.
  • CONCLUSION: Significantly higher expression of MMP-7 and MMP-9 in tumor tissue than in the surrounding tissue or in benign lung disease tissue supports the notion of an important role of these metalloproteinases in the growth of lung carcinoma.
  • TIMP-1 expression is increased only in carcinoma, but not in benign lung disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Diseases / metabolism. Lung Neoplasms / metabolism. Matrix Metalloproteinase 7 / genetics. Matrix Metalloproteinase 9 / genetics. Tissue Inhibitor of Metalloproteinase-1 / genetics. Tissue Inhibitor of Metalloproteinase-2 / genetics


35. Dujon C, Azarian R, Petitpretz P: [Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study]. Rev Mal Respir; 2009 Nov;26(9):952-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study].
  • [Transliterated title] Longs survivants de cancers bronchiques non à petites cellules stades IIIB-IV.
  • INTRODUCTION: The prognosis of non-small cell lung cancer (NSCLC) is poor, especially for advanced stages IIIB-IV.
  • A small number of patients survive more than 2 years after diagnosis; they are called long term survivors (LS).
  • METHODS: A retrospective study in the respiratory department of a general hospital including all patients with a proven diagnosis of NSCLC stage IIIB and IV.
  • Two thirds of the patients were PS 0-1, 84.6% were stage IIIBw-IV.
  • Adenocarcinoma was the predominant histological type.
  • Univariate analysis revealed that long term survival was associated with a Charlson's score < or = 2, PS 0-1, a normal white blood cell count at diagnosis, adenocarcinoma histology, response (RP) to first line treatment and treatment with a tyrosine-kinase inhibitor (TKI).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Survivors
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953041.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


36. Malignancy Study Group of Izmir Training and Research Hospital for Thoracic Medicine and Surgery (ITRHTMS): Temporal changes in lung cancer: a 10-year study in a chest hospital. Monaldi Arch Chest Dis; 2008 Dec;69(4):157-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal changes in lung cancer: a 10-year study in a chest hospital.
  • BACKGROUND AND AIM: No prospective, wide-scale study on lung cancer (LC) exists in Turkey.
  • Frequent types were squamous cell carcinoma (24.7%), small cell carcinoma (SCLC) (14.2%) and adenocarcinoma (13.2%).
  • Adenocarcinoma in the younger group (<40), females or non-smokers, and squamous cell carcinoma in the older group, males or smokers were the leading types.
  • Non-small cell lung carcinoma (NSCLC) was mostly diagnosed at stages IIIB (36.7%) and IV (37%) whereas SCLC at limited stage (59.1%).
  • The most common type is squamous cell carcinoma in males, and adenocarcinoma in females.
  • NSCLC is diagnosed more frequently at advanced stage but SCLC at limited stage.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Monaldi Arch Chest Dis. 2009 Sep;71(3):135. Halilcolar, H [removed]; Yapicioglu, S [removed]; Bilaceroglu, S [removed]
  • (PMID = 19350837.001).
  • [ISSN] 1122-0643
  • [Journal-full-title] Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
  • [ISO-abbreviation] Monaldi Arch Chest Dis
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Investigator] Bilaceroglu S; Cimen P; Cirak K; Erer O; Guclu SZ; Halilcolar H; Ozacar R; Ozden E; Ozkan S; Ozsoz A; Polat G; Tellioglu E; Tibet G; Tuksavul F; Yapicioglu S
  •  go-up   go-down


37. Shibata H, Nomori H, Uno K, Iyama K, Tomiyoshi K, Nakashima R, Sakaguchi K, Goya T, Takanami I, Koizumi K, Suzuki T, Kaji M, Horio H: 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness. Ann Nucl Med; 2009 Sep;23(7):609-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness.
  • BACKGROUND: To determine the usefulness of positron emission tomography (PET) with (11)C-acetate (AC) for imaging lung adenocarcinoma and evaluating its tumor aggressiveness, AC- and (18)F-fluorodeoxyglucose (FDG)-PET were compared.
  • METHODS: One hundred and sixty-nine adenocarcinomas with clinical stage IA and 53 benign nodules were examined by both AC- and FDG-PET before surgery.
  • The sensitivity and specificity for discriminating benign/adenocarcinoma were compared between AC- and FDG-PET.
  • The AC and FDG uptakes were examined to determine the relationship with tumor aggressiveness, i.e., pathological tumor stage, lymphatic, vascular, or pleural involvement, and proliferative activity determined by Ki-67 staining score.
  • RESULTS: While the sensitivity of AC-PET was significantly higher than FDG-PET for bronchioloalveolar carcinoma (BAC) and well-differentiated (W/D) adenocarcinoma (p < 0.001 and 0.006, respectively), there was no significant difference for moderately or poorly differentiated adenocarcinoma.
  • While FDG uptakes were significantly higher in tumors with pathological advanced stages or those with lymphatic, vascular and/or pleural involvements than in tumors with pathological stage IA or those without these tumor involvements (p = 0.04 to p < 0.001), AC uptake did not show significant differences between the respective sub-groups except according to the tumor stage.
  • CONCLUSIONS: While AC-PET can image BAC and W/D adenocarcinoma with a higher sensitivity than FDG-PET, it cannot evaluate tumor aggressiveness of clinical stage IA lung adenocarcinoma as well as FDG-PET.
  • [MeSH-major] Acetates. Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Carbon. Fluorodeoxyglucose F18. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562438.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Acetates; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


38. Borczuk AC, Qian F, Kazeros A, Eleazar J, Assaad A, Sonett JR, Ginsburg M, Gorenstein L, Powell CA: Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol; 2009 Mar;33(3):462-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive size is an independent predictor of survival in pulmonary adenocarcinoma.
  • Current classification of pulmonary adenocarcinoma includes noninvasive bronchioloalveolar carcinoma, mixed subtype adenocarcinoma, and several patterns of invasive carcinoma.
  • The extent of invasion in mixed subtype adenocarcinoma is variable, and prior studies suggest that estimates of extent of desmoplasia or invasion and gross tumor size are predictors of survival.
  • Pathologic review of 178 consecutive primary lung adenocarcinoma resections from 1997 to 2000 was performed blinded to outcome.
  • In multivariate analysis and in strata adjusted for stage, measurement of linear extent of invasion was significantly associated with survival whereas gross size measurement alone was not.
  • In conclusion, among lung adenocarcinomas, histologic assessment of invasive growth may provide valuable prognostic information, and tumors with invasion under 0.6 cm have a more indolent clinical course after resection.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 15;88(6):1403-9 [10717623.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):8-13 [15660697.001]
  • [Cites] Chest. 2000 Jun;117(6):1568-71 [10858384.001]
  • [Cites] Nucl Med Commun. 2000 Aug;21(8):707-14 [11039452.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jun;176(6):1399-407 [11373200.001]
  • [Cites] Radiology. 2001 Sep;220(3):803-9 [11526285.001]
  • [Cites] Lung Cancer. 2002 Jun;36(3):289-95 [12009240.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2134-42 [12001109.001]
  • [Cites] Ann Thorac Surg. 2002 Nov;74(5):1635-9 [12440622.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2546-54 [12467069.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Mar;23(3):409-14 [12614815.001]
  • [Cites] Ann Thorac Surg. 2003 May;75(5):1601-5; discussion 1605-6 [12735586.001]
  • [Cites] Semin Roentgenol. 2005 Apr;40(2):90-7 [15898407.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):195-207 [16341153.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):233-41 [17192789.001]
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):706-14 [17762336.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1532-41 [17702091.001]
  • [Cites] Histopathology. 2008 Jan;52(2):147-57 [18184264.001]
  • [Cites] Chest. 2003 Nov;124(5):1828-33 [14605056.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1571-6 [14657718.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):61-8 [15013584.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):198-206 [15043309.001]
  • [Cites] Obstet Gynecol. 1976 Nov;48(5):571-8 [980284.001]
  • [Cites] Am J Surg Pathol. 1980 Aug;4(4):365-73 [7425202.001]
  • [Cites] Radiology. 1991 May;179(2):469-76 [2014294.001]
  • [Cites] J Reprod Med. 1994 Sep;39(9):671-3 [7807476.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1412-9 [9865826.001]
  • [Cites] Radiographics. 2004 Nov-Dec;24(6):1617-36; discussion 1632-6 [15537972.001]
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • (PMID = 19092635.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA120174-03; United States / NCI NIH HHS / CA / R01 CA120174; United States / NCI NIH HHS / CA / R01 CA120174-03
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS251532; NLM/ PMC2987634
  •  go-up   go-down


39. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR: Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res; 2009 Nov 1;69(21):8341-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
  • In a subset of lung adenocarcinomas, the epidermal growth factor receptor (EGFR) is activated by kinase domain mutations and/or gene amplification, but the interaction between the two types of abnormalities is complex and unclear.
  • For this study, we selected 99 consecutive never-smoking women of East Asian origin with lung adenocarcinomas that were characterized by histologic subtype.
  • We analyzed EGFR mutations by PCR-capillary sequencing, EGFR copy number abnormalities by fluorescence and chromogenic in situ hybridization and quantitative PCR, and EGFR expression by immunohistochemistry with both specific antibodies against exon 19 deletion-mutated EGFR and total EGFR.
  • Lung adenocarcinomas with EGFR amplification had significantly more EGFR exon 19 deletion mutations than adenocarcinomas with disomy, and low and high polysomy (100% versus 54%, P = 0.009).
  • EGFR amplification occurred invariably on the mutated and not the wild-type allele (median mutated/wild-type ratios 14.0 versus 0.33, P = 0.003), was associated with solid histology (P = 0.008), and advanced clinical stage (P = 0.009).
  • EGFR amplification was focally distributed in lung cancer specimens, mostly in regions with solid histology.
  • Patients with EGFR amplification had a significantly worse outcome in univariate analysis (median disease-free survival, 16 versus 31 months, P = 0.01) and when adjusted for stage (P = 0.027).
  • Lung adenocarcinomas with EGFR amplification have a unique association with exon 19 deletion mutations and show distinct clinicopathologic features associated with a significantly worsened prognosis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3023-8 [19366827.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2046-53 [17332333.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2248-55 [17538169.001]
  • [Cites] Mod Pathol. 2007 Oct;20(10):1028-35 [17673923.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):340-7 [18379350.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2106-11 [18381415.001]
  • [Cites] J Mol Diagn. 2008 May;10(3):242-8 [18403609.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):810-27 [18391747.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1367-80 [18815398.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):226-35 [15665299.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94 [16106023.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8 [16467085.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Aug;1(3):192-200 [19138956.001]
  • [Cites] PLoS One. 2009;4(2):e4576 [19238210.001]
  • [Cites] Am J Clin Pathol. 2006 Jun;125(6):860-5 [16690485.001]
  • (PMID = 19826035.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA090578-01A10003; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / R0I CA114465; United States / NCI NIH HHS / CA / R01 CA114465; United States / NCI NIH HHS / CA / P20 CA090578-01A10003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS143923; NLM/ PMC2783286
  •  go-up   go-down


40. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y: Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol; 2007 Feb;20(2):208-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, we used the reverse transcription-polymerase chain reaction (RT-PCR) to show that mammaglobin (MGB1) can serve as a differential marker of breast cancer metastasis from primary lung cancer.
  • Of the other cancers examined, including 29 of the head and neck, eight of the thyroid, 106 of the lung, 35 of the gastrointestinal tract, three of the pancreas, 14 of the uterine cervix and 13 of the ovary, none were positive for MGB1 except a proportion of salivary gland tumors (6/11, 55%) and endometrial cancers (3/23, 13%).
  • Clinicopathologically, MGB1 expression was associated with positive expression of estrogen receptors and negative expression of CK5, but not with pathological stage, HER2 gene amplification or p53 immunoreactivity.
  • In terms of practical diagnosis, MGB1 immunohistochemistry can serve as a differential marker of breast cancer metastasis from primary lung cancer for two reasons.
  • Secondly, as primary lung adenocarcinomas may express estrogen receptors, MGB1 expression provides further discrimination of the origin of breast cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. Uteroglobin / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Count. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Japan / epidemiology. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mammaglobin A. Neoplasm Staging. Receptors, Estrogen / metabolism. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192791.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


41. Higashi K, Sakuma T, Ito K, Niho S, Ueda Y, Kobayashi T, Sekiguchi R, Takahashi T, Kato T, Tonami H: Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma. Eur J Nucl Med Mol Imaging; 2009 Mar;36(3):373-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma.
  • PURPOSE: Patients with the same pathological stage of lung adenocarcinoma display marked variability in postoperative recurrence.
  • The aim of this study was to predict the postoperative prognosis in patients with small-sized pulmonary adenocarcinoma on the basis of FDG uptake on PET, the extent of ground-glass opacity (GGO) on CT, and serum carcinoembryonic antigen (CEA) levels.
  • METHODS: We evaluated 87 patients (40 men, 47 women; mean age 64 years, age range 42-84 years) with lung adenocarcinoma of 3.0 cm or smaller.
  • CONCLUSION: Combined evaluation of preoperative FDG uptake, GGO, and serum CEA level may enable patients with T1 lung adenocarcinoma at low risk and at high risk of postoperative recurrence to be identified.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Lung Neoplasms / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 2004 May;25(5):877-83 [15082298.001]
  • [Cites] Ann Thorac Surg. 2004 Apr;77(4):1157-61; discussion 1161-2 [15063225.001]
  • [Cites] AJR Am J Roentgenol. 2001 Dec;177(6):1417-22 [11717098.001]
  • [Cites] Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3 [7677489.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):61-8 [15013584.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):267-73 [15695786.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2546-54 [12467069.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):559-66 [15073250.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 May;33(5):819-23 [18374589.001]
  • [Cites] Clin Radiol. 2008 Aug;63(8):856-63 [18625349.001]
  • [Cites] Eur J Nucl Med. 2001 Feb;28(2):155-64 [11303885.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):214-20 [17268017.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1448-54 [17532938.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Jan;135(1):44-9 [18179917.001]
  • [Cites] Radiology. 2001 Sep;220(3):803-9 [11526285.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1136-43 [15718309.001]
  • [Cites] Ann Thorac Surg. 2005 Mar;79(3):984-8; discussion 989 [15734419.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jul;173(1):75-9 [10397103.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1016-20 [9627336.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3601-5 [16101187.001]
  • [Cites] J Clin Pathol. 1992 Jul;45(7):591-3 [1517458.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Jun;25(6):1102-6 [15145016.001]
  • [Cites] Lancet Oncol. 2004 Sep;5(9):531-40 [15337482.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Oct;108(4):684-6 [7934103.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1129-32 [15100107.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):75-80 [15598942.001]
  • (PMID = 18931837.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


42. Shim SS, Han J: FDG-PET/CT imaging in assessing mucin-producing non-small cell lung cancer with pathologic correlation. Ann Nucl Med; 2010 Jun;24(5):357-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT imaging in assessing mucin-producing non-small cell lung cancer with pathologic correlation.
  • OBJECTIVE: The objective of this study was to describe the PET/CT findings of mucin-producing non-small cell lung cancer (NSCLC) and how those findings are associated with pathology.
  • METHODS: A review of all patients with FDG-PET/CT identified 11 patients with histopathologically confirmed mucin-producing NSCLC; 3 mucinous bronchioloalveolar carcinoma (mBAC), 5 mixed-type adenocarcinoma with prominent mucinous BAC pattern (ADENO + mBAC), and 3 mixed-type adenocarcinoma with mucin production (ADENO + MUCIN) in our institute.
  • The mean SUV of pure mBAC was 1.93, that of mucin-producing adenocarcinoma was 2.69 without a significant difference (p = 0.279).
  • No significant correlations between tumor size or stage and SUV were determined.
  • The SUV in mBACs were lower than the other types of mucin-producing adenocarcinoma; however, we determined no significant difference to exist between the SUVs of two groups of lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Mucins / metabolism. Positron-Emission Tomography. Tomography, X-Ray Computed


43. Ren SH, Wang JW, Zhang L: [Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells]. Zhonghua Yi Xue Za Zhi; 2005 Jun 15;85(22):1530-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells].
  • OBJECTIVE: To investigate the effect of synthesized Her-2/neu specific siRNA on the cell cycle and apoptosis of Her-2/neu upregulating human lung adenocarcinoma cells.
  • METHODS: Human lung cancer cells of the line calu-3 were cultured and divided into 4 groups: untreated control group, blank vector group transfected with blank vector, non-specific siRNA group transfected with unrelated siRNA, and Her2/neu siRNA group transfected with Her2/neu siRNA.
  • Forty-eight hours after transfection, the expression rate of Her-2/neu protein was 25.0% +/- 1.6% in the calu-3 cells transfected with Her-2/neu siRNA, significantly lower than in the control group, blank vector group, and non-specific siRNA group (98.2% +/- 2.2%, 95.7% +/- 2.0%, and 94.8% +/- 1.6% respectively, all P < 0.01); the proportion of the cells in G(0)/G(1) stage increased and those in the S stage decreased in the celu-3 cells transfected with Her-2/neu siRNA, and the proportions of the cells in G(0)/G(1) stage and Stage did not significantly change (F = 6.1, P < 0.01); the apoptotic rate of the Her2/neu siRNA group was 25.1% +/- 1.2%, significantly higher than those of the other 3 groups (4.8% +/- 0.5%, 8.6% +/- 0.9%, and 10.3% +/- 0.3% respectively, all P < 0.01); the caspase-3 activity ratio of the Her2/neu siRNA group was 134.6% +/- 4.5%, significantly higher than those in the blank vector group and non-specific siRNA group (105.0% +/- 2.5% and 112.0% +/- 2.8% respectively, both P < 0.01), and the VEGF level in the supernatant of the Her2/neu siRNA group was 176 pg/ml +/- 6 pg/ml, significantly lower than those of the control group, blank vector group, and non-specific siRNA group (476 pg/ml +/- 13 pg/ml, 426 pg/ml +/- 9 pg/ml, and 406 pg/ml +/- 9 pg/ml respectively, all P < 0.01).
  • CONCLUSION: Chemically synthesized Specific Her-2/neu targeting siRNA effectively inhibits Her-2/neu expression and leads to the decline of cyclin D(1) and VEGF levels and activation of caspase-3 pathway thus arresting the cell cycle at G(0)/G(1) stage and enhancing cell apoptosis.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis / physiology. Gene Silencing. Lung Neoplasms / pathology. Receptor, ErbB-2 / biosynthesis


44. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR, Southwest Oncology Group: Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol; 2009 Jan;4(1):87-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
  • INTRODUCTION: Bortezomib is a small-molecule proteasome inhibitor with single-agent activity in patients with non-small cell lung carcinoma (NSCLC) and synergy with gemcitabine in preclinical studies.
  • METHODS: Patients with selected stage IIIB/IV NSCLC, performance status 0-1, and no history of brain metastasis received up to six 21-day cycles of gemcitabine 1000 mg/m, days 1 and 8, carboplatin area under curve 5.0, day 1, and bortezomib 1.0 mg/m, days 1, 4, 8, and 11.
  • RESULTS: One-hundred-fourteen patients (52% adenocarcinoma, 85% stage IV) received a median of 3.6 treatment cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adult. Aged. Boronic Acids / administration & dosage. Bortezomib. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cohort Studies. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Pyrazines / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):11-7 [11516199.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Lung Cancer. 2002 Jul;37(1):9-14 [12057861.001]
  • [Cites] Oncologist. 2002;7(3):226-33 [12065795.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2505-11 [12171876.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4285-91 [12409326.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1145-54 [12631620.001]
  • [Cites] Lung Cancer. 2003 Jul;41(1):81-9 [12826316.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S89-96 [12867067.001]
  • [Cites] Lung Cancer. 2003 Sep;41(3):321-31 [12928123.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):33714-23 [12821677.001]
  • [Cites] Cancer Sci. 2004 Feb;95(2):176-80 [14965369.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5022-6 [15297403.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):343-53 [15197486.001]
  • [Cites] Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):13-20 [15339054.001]
  • [Cites] Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):21-6 [15339055.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2004 Spring;16(1):28-39 [15366685.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14 [15464472.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):190-6 [15625373.001]
  • [Cites] Clin Lung Cancer. 2004 Dec;6 Suppl 2:S89-96 [15638966.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3777-84 [16099887.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9097-104 [16361616.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):177-89 [16427303.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3113-20 [16754936.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):781-92 [16847887.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5025-33 [17075122.001]
  • [Cites] Oncology (Williston Park). 2006 Nov;20(12):1515-24; discussion 1524-5, 1530, 1535 [17153906.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):317-23 [17079694.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):68-74 [18166843.001]
  • (PMID = 19096312.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86780; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / U10 CA035128; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / U10 CA063850; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / U10 CA032102-32; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / U10 CA180846; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 0W860991D6 / Deoxycytidine; 69G8BD63PP / Bortezomib; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS244778; NLM/ PMC3024911
  •  go-up   go-down


45. Yoshino I, Osoegawa A, Yohena T, Kameyama T, Oki E, Oda S, Maehara Y: Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma. Respir Med; 2005 Mar;99(3):308-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma.
  • BACKGROUND: In non-small cell lung cancer, a loss of heterozygosity (LOH) is frequently observed; however, few studies have investigated the differences in the LOH status between adenocarcinoma and squamous cell carcinoma.
  • RESULTS: LOH was more frequently observed in squamous cell carcinoma (20 of 22, 90%) than in adenocarcinomas (33 of 49, 67%) (P=0.0348), and the number of LOH per patient was also higher in the patients with squamous cell carcinoma (2.2+/-1.4) than in those with adenocarcinoma (1.5+/-1.2, P=0.037).
  • In adenocarcinomas, the number of LOH per patients correlated significantly with the pack-year index, whereas the pathological stage significantly affected the number of LOH in squamous cell carcinomas.
  • CONCLUSION: The presence of LOH is relatively uncommon in adenocarcinoma of the lung; however, the incidence of LOH tends to be associated with the smoking status.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Loss of Heterozygosity / genetics. Lung Neoplasms / genetics


46. Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK, Song Y: Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol; 2009 Sep;4(9):1094-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.
  • However, the prognostic value of VEGF overexpression in patients with lung cancer remains controversial.
  • A systematic review of eligible studies with meta-analysis was performed to quantitatively review the correlation of VEGF overexpression with survival in patients with lung cancer.
  • The studies were categorized by histology, disease stage, patient race, VEGF isoform, and laboratory techniques used.
  • Combined hazard ratios suggested that VEGF overexpression had an unfavorable impact on survival of patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
  • In stage I-III NSCLC with VEGF, the hazard ratio (95% confidence interval) was 1.46 (1.38-1.54) overall, 1.35 (1.24-1.46) in Asian patients, 1.61 (1.49-1.73) in non-Asian patients, 1.41 (1.17-1.65) in SCLC, 1.27 (1.06-1.47) in adenocarcinoma, 1.57 (1.43-1.70) in stage I NSCLC, 1.46 (1.38-1.55) in NSCLC by immunohistochemistry, 1.52 (1.23-1.81) in NSCLC by reverse transcription-polymerase chain reaction, 1.22 (0.96-1.47) in NSCLC with VEGFC, and 1.58 (0.96-2.20) in NSCLC with VEGFR3/flt-1.
  • The data collected were not sufficient to determine the prognostic value of VEGF in patients with squamous cell lung carcinomas.
  • [MeSH-major] Lung Neoplasms / mortality. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / mortality. Humans. Prognosis. Publication Bias. Vascular Endothelial Growth Factor Receptor-3 / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687765.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  • [Number-of-references] 87
  •  go-up   go-down


47. Lin DM, Ma Y, Liu XY, Zheng S, Xue LY, Liu XY, Zou SM, Lü N, He ZG, Liu FS: [Prognostic significance of micropapillary pattern in pulmonary adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Mar;35(3):151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of micropapillary pattern in pulmonary adenocarcinoma].
  • OBJECTIVE: To evaluate the prognostic significance of micropapillary pattern (MPP) in adenocarcinoma of lung.
  • METHODS: Ninety-one consecutively excised cases of pulmonary adenocarcinoma, including follow-up data, were retrospectively studied.
  • The 5-year survival rates were 88.9% for stage I tumors, 46.2% for stage II tumors, and 23.8% for stage III tumor respectively (P = 0.000).
  • The extent of micropapillary component showed no correlation with tumor stage, size and 5-year survival rate (P = 0.065, 0.358 and 0.206, respectively).
  • In pulmonary adenocarcinoma, this characteristic histology correlated with tumor stage and size, but not with patient's gender and smoking history.
  • Within the same stage, the 5-year survival rates of MPP-positive and MPP-negative groups were as follows: for stage I, 78.6% versus 92.6% (P = 0.1548), for stage II, 30.0% versus 100% (P = 0.0598), and for stage III, 17.7% versus 28.6% (P = 0.4045).
  • CONCLUSIONS: MPP in primary pulmonary adenocarcinoma, even when only constituting a minor component, predicts an aggressive clinical behavior and is associated with poor prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Papillary / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adult. Aged. Female. Follow-Up Studies. Humans. Lung / pathology. Lung / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630503.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH: High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol; 2010 Mar;5(3):305-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
  • We investigate the clinicopathologic features of MET gene copy in nonsmall cell lung cancer (NSCLC).
  • EGFR and MET GCNs were studied using fluorescence in situ hybridization (FISH) and were estimated according to the University of Colorado Cancer Center (UCCC) criteria.
  • MET gene copy status was not associated with gender, smoking history, histology, or stage.
  • However, true MET amplification was more frequent in patients with SCC than in those with adenocarcinoma.
  • CONCLUSIONS: Our results suggest that increased MET GCN would be an independent poor prognostic factor in SCC of the lung.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Squamous Cell / mortality. Gene Dosage. Lung Neoplasms / mortality. Proto-Oncogene Proteins c-met / genetics. Receptors, Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Genotype. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Risk Factors. Survival Rate


49. Ancona E, Cagol M, Epifani M, Cavallin F, Zaninotto G, Castoro C, Alfieri R, Ruol A: Surgical complications do not affect longterm survival after esophagectomy for carcinoma of the thoracic esophagus and cardia. J Am Coll Surg; 2006 Nov;203(5):661-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The longterm prognosis for patients undergoing operation depends largely on the pathologic stage of the disease.
  • STUDY DESIGN: A retrospective analysis was performed on patients with squamous cell carcinoma and adenocarcinoma of the thoracic esophagus and esophagogastric junction, undergoing surgical resection between January 1992 and December 2002.
  • CONCLUSIONS: Surgical complications have no negative impact on survival rates, which seem to depend exclusively on the pathologic stage of the tumor.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Cardia. Esophageal Neoplasms / surgery. Esophagectomy / adverse effects. Stomach Neoplasms / surgery
  • [MeSH-minor] Comorbidity. Female. Heart Diseases / epidemiology. Humans. Length of Stay. Lung Diseases / epidemiology. Male. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084327.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Sonobe M, Nakagawa M, Takenaka K, Katakura H, Adachi M, Yanagihara K, Otake Y, Wada H, Tanaka F: Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol; 2007 Jan 1;95(1):63-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
  • BACKGROUND AND OBJECTIVES: In this paper we examined the influence of epidermal growth factor receptor (EGFR) gene mutations on EGFR expression, downstream mediators, and survival in patients with non-small cell lung cancer (NSCLC).
  • METHODS: We retrospectively analyzed the tumors of 53 patients with completely resected pathological stage I-IIIA NSCLC for the presence of EGFR gene mutations, the expression of EGFR mRNA and protein, phosphoryl-Akt, and phosphoryl-mitogen-activated protein kinase (MAPK) using immunostaining, and patients' prognosis.
  • However, the 5-year survival rate of patients with either a stage I adenocarcinoma or large cell carcinoma who had an EGFR mutation was significantly greater than for those who did not have such a mutation (92% vs. 57%, P = 0.037).
  • In early stage NSCLC, the presence of an EGFR gene mutation bode well for the patient's prognosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Genes, erbB-1 / genetics. Lung Neoplasms / metabolism. Mutation. Receptor, Epidermal Growth Factor / metabolism


51. Brandão DS, Haddad R, Marsico GA, Boasquevisque CH: [Clinicopathological aspects of and survival in patients with clinical stage I bronchioloalveolar carcinoma]. J Bras Pneumol; 2010 Mar-Apr;36(2):167-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological aspects of and survival in patients with clinical stage I bronchioloalveolar carcinoma].
  • OBJECTIVE: To analyze the clinicopathological aspects of bronchioloalveolar carcinoma (BAC) and the survival in a sample of patients at clinical stage I.
  • METHODS: A retrospective study involving 26 patients diagnosed with clinical stage I BAC and undergoing surgery at the Thoracic Diseases Institute of the Federal University of Rio de Janeiro, in the city of Rio de Janeiro, Brazil, between 1987 and 2007.
  • The mean age at diagnosis was 68.5 years.
  • Stage IB was the most common pathological stage, followed by stages IA and IIB (46.2%, 38.4% and 15.4%, respectively).
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20485936.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


52. Chong CF, Khoo KL, Lim TK, Chang AY, Lim HL, Lee CN, Wong PS: Comparison of clinical with pathological nodal staging from systematic mediastinal lymph node dissection in early resectable non-small cell lung cancer. Singapore Med J; 2007 Jul;48(7):620-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of clinical with pathological nodal staging from systematic mediastinal lymph node dissection in early resectable non-small cell lung cancer.
  • INTRODUCTION: We compared the accuracy of clinical nodal (cN) status N0-1 with that of pathological nodal (pN) status obtained from systematic mediastinal lymph node dissection (SMLD) in primary non-small cell lung cancer.
  • METHODS: Data from 22 consecutive patients, who underwent lung cancer resection and SMLD of at least three mediastinal lymph node stations, from November 2001 to May 2003, were ana1ysed retrospectively.
  • 41 percent had squamous cell carcinoma, 45.5 percent had adenocarcinoma, and 4.5 percent each had large cell carcinoma, bronchioalveolar carcinoma or a lymphoepithelial carcinoma. pN2 metastases were found in 27.3 percent of patients.
  • The sensitivity of cN0-1 was only 12.5 percent, with a specificity of 92.9 percent and an area under the receiver operating characteristics curve of 0.53.
  • 41 percent of patients were understaged with 27.3 percent in pathological stage III.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology. Neoplasm Staging / methods. Tomography, X-Ray Computed


53. Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F, Favaretto A: Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res; 2010 Dec;30(12):5121-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.
  • BACKGROUND/AIM: Gefitinib and erlotinib were shown to be particularly effective in a clinically selected subpopulation of non-small cell lung cancer patients (NSCLC): adenocarcinoma histology, non-smoking status, Asian origin and female gender have been associated with improved clinical benefit compared to the unselected NSCLC population.
  • The aim of the present study was to investigate the prognostic and predictive role of EGFR and KRAS analysis in advanced lung adenocarcinomas, selected according to clinical features associated to better response to EGFR tyrosine kinase inhibitors (TKIs), namely female gender and non-smoker or former light smoker status.
  • CONCLUSION: In a group of clinically selected patients, EGFR and KRAS analysis was able to define distinct molecular subsets of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-1. Genes, ras. Lung Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187500.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


54. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Jones DR: Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg; 2009 Apr;35(4):699-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both FDG-PET maximal positron emission tomography (PET) standardized uptake values (SUVmax) and selected tumor markers have been shown to correlate with stage, nodal disease, and survival in esophageal cancer.
  • METHODS: FDG-PET SUVmax was calculated in 67 patients with esophageal cancer of which 59 (88%) had adenocarcinoma.
  • Pathologic staging included stage I (n=29, 43%), stage II (n=19, 28%), stage III disease (n=18, 27%), and stage IV disease (n=1, 2%).
  • PET SUVmax correlated with T stage (p=0.001).

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):663-9 [11505413.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):428-32 [12560430.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Feb;125(2):246-53 [12579092.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 May;125(5):1121-31 [12771886.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):890-4 [14624783.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2579-83 [15330218.001]
  • [Cites] Science. 1987 Mar 20;235(4795):1492-5 [3103217.001]
  • [Cites] Annu Rev Physiol. 1992;54:911-30 [1562197.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1637-42 [8253340.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):303-5 [9149888.001]
  • [Cites] Dis Esophagus. 2005;18(3):185-9 [16045581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1053-9 [15964705.001]
  • [Cites] Ann Thorac Surg. 2006 Mar;81(3):1076-81 [16488726.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):631-4 [16731604.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7 [16857803.001]
  • [Cites] Ann Thorac Surg. 2006 Aug;82(2):391-4; discussion 394-5 [16863735.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jul;36(7):403-9 [16782729.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1054-62 [16865594.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):977-91 [17122988.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):658-67 [17211865.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Mar;133(3):738-45 [17320575.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1377-83 [17437013.001]
  • [Cites] Lung Cancer. 2008 Feb;59(2):203-10 [17913282.001]
  • (PMID = 19136271.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL007849-09; United States / NHLBI NIH HHS / HL / T32 HL007849; United States / NHLBI NIH HHS / HL / T32 HL007849-09
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS189314; NLM/ PMC2878130
  •  go-up   go-down


55. Herpel E, Muley T, Schneider T, Palm E, Kieslich de Hol D, Warth A, Meister M, Storz K, Schnabel PA, Schirmacher P, Dienemann H, Hoffmann H: A pragmatic approach to the diagnosis of nodal micrometastases in early stage non-small cell lung cancer. J Thorac Oncol; 2010 Aug;5(8):1206-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pragmatic approach to the diagnosis of nodal micrometastases in early stage non-small cell lung cancer.
  • INTRODUCTION: This study was designed to develop a both sensitive and efficient algorithm for detection of lymph node micrometastases and to determine its prognostic impact in patients with early stage non-small cell lung cancer (NSCLC).
  • METHODS: One hundred seventy patients with NSCLC p stage I and II were included in this study, of which n = 5299 lymph nodes were obtained and submitted to histopathologic analysis.
  • Survival differences between patients who were upstaged into stage II (N0>N1) and those remaining in stage I were not statistically significant (p = 0.537).
  • CONCLUSION: Extended workup of N2-lymph nodes using one broad-spectrum keratin marker in otherwise N2-negative lymph nodes may represent a both efficient and sensitive approach to the identification of micrometastases in dissected lymph nodes of patients with early stage NSCLC.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Nodes / pathology. Neoplasms, Squamous Cell / secondary
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581709.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, Choi HS, Kang HJ, Hahn S, Kang CH, Sung SW, Kim JH: Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer; 2008 Jan;59(1):111-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
  • Recent studies have reported that clinical response to epidermal growth factor receptor (EGFR) inhibitors is associated with somatic changes of EGFR in the advanced stage of lung cancer.
  • However, there is no clear data demonstrating whether such molecular changes of EGFR per se can affect the clinical outcome of early stage cancer after surgical resection.
  • DNA mutations of EGFR and KRAS were investigated in 71 adenocarcinoma patients who received surgical resection.
  • Fluorescence in situ hybridization (FISH) of EGFR gene amplification was performed in 48 samples.
  • However, the EGFR mutation was not associated with age, gender, or clinical stage.
  • The amplification of EGFR copy was frequently observed in the female gender (12/29 (41.4%):3/19 (15.8%); p=0.061) and in the advanced stage (> or =Stage IIIA, 9/19 (47.4%):6/29 (20.7%); p=0.051).
  • KRAS mutations (p=0.000), male gender (p=0.001), absence of BAC feature (p=0.003), advanced stage (p=0.039), and smoking history (p=0.030) were poor prognostic factors for overall survival, whereas EGFR mutation (p=0.184) and amplification (p=0.756) were not.
  • The presence of EGFR mutation was not a prognostic factor of the clinical outcome of early lung cancer after surgical resection.
  • This result provides an important message for the protocol design of future trials of EGFR inhibitors in early lung cancer.
  • DNA mutations of EGFR and KRAS were investigated in 71 adenocarcinoma patients who received surgical resection.
  • Whereas KRAS mutation was a poor prognostic factor, EGFR mutation was not, and its presence per se did not affect the clinical outcome of early lung cancer after surgical resection.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904685.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


57. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Zhao YD, Liepa AM, Peterson P, Tonato M: The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol; 2009 Dec;4(12):1568-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
  • INTRODUCTION: Although histology has not consistently been associated with treatment outcome in advanced non-small cell lung cancer, a recent phase III trial comparing pemetrexed plus cisplatin and gemcitabine plus cisplatin (GC) demonstrated better efficacy for pemetrexed plus cisplatin in nonsquamous (adenocarcinoma and large cell carcinoma) carcinoma than in squamous cell carcinoma.
  • Herein, retrospective analysis is used to explore the potential predictive and prognostic role of non-small cell lung cancer histology in patients treated with three first-line, platinum-based regimens.
  • Using Cox multiple regression, factors for one model included treatment (PCb, GC, and VC), histology (squamous, adenocarcinoma, large cell, and other), gender, Eastern Cooperative Oncology Group performance status (0/1 and 2), stage (IIIB and IV), number of metastatic sites (< or = 1 and >1), and smoking history (yes or no).
  • Subsequent pairwise comparisons of histology groups demonstrated a survival advantage for squamous cell carcinoma over adenocarcinoma (p = 0.0021).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Paclitaxel / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009911.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


58. Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F: Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg; 2008 May;33(5):829-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
  • INTRODUCTION: Optimal preoperative treatment of stage IIB (Pancoast)/III non-small cell lung cancer (NSCLC) remains undetermined and a subject of controversy.
  • RESULTS: From 1996 to 2005, 107 pts were initially selected for treatment and received induction chemoradiation (stage IIB-Pancoast 18, IIIA 58 and IIIB 31, squamous cell carcinoma 48%, adenocarcinoma 44%, large-cell undifferentiated carcinoma 14%).
  • CONCLUSION: Surgery was feasible after induction chemoradiation, particularly lobectomy in PS 0-1, stage IIB (Pancoast)/III NSCLC pts but pneumonectomy carries a high risk of postoperative death (particularly, right pneumonectomy).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Lung Neoplasms / drug therapy. Radiotherapy, Conformal / methods


59. Nosotti M, Tosi D, Palleschi A, Rosso L, Mendogni P, Santambrogio L: Immunocytochemical detection of occult tumor cells in the bone marrow: prognostic impact on early stages of lung cancer. Eur Surg Res; 2008;41(3):267-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical detection of occult tumor cells in the bone marrow: prognostic impact on early stages of lung cancer.
  • OBJECTIVES: This study was designed to verify the prognostic impact of occult tumor cells in the bone marrow of stage I and II non-small-cell lung cancer patients using cytokeratin as a micrometastatic marker.
  • METHODS: One hundred and fifty-two patients with stage I and II non-small-cell lung cancer, who underwent radical surgery by pulmonary lobectomy, were entered into the study.
  • The prevalence of the occult tumor cells was not related to age, gender, tumor stage, histological differentiation or grade.
  • This result did not change when grouping the patients by tumor stage.
  • The stage was the best predictor of cancer recurrence (Cox proportional hazards model ratio: 2.09; p = 0.0026).
  • CONCLUSIONS: This study confirms that immunocytochemical analysis detects occult tumor cells in the bone marrow of at least 25% of patients surgically treated for stage I and II non-small-cell lung cancer.
  • [MeSH-major] Bone Marrow Neoplasms / metabolism. Bone Marrow Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Bone Marrow / metabolism. Bone Marrow / pathology. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Immunohistochemistry. Keratin-18 / metabolism. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18594145.001).
  • [ISSN] 1421-9921
  • [Journal-full-title] European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes
  • [ISO-abbreviation] Eur Surg Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Keratin-18
  •  go-up   go-down


60. Funakoshi Y, Takeda S, Kadota Y, Kusu T, Maeda H: Clinical characteristics and surgery of primary lung cancer in younger patients. Asian Cardiovasc Thorac Ann; 2008 Oct;16(5):387-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and surgery of primary lung cancer in younger patients.
  • Controversy exists regarding the clinical characteristics, pathological findings, and prognosis of patients < 50 years of age with primary lung cancer.
  • The medical records of 4,556 patients diagnosed with primary lung cancer between 1980 and 2004 were reviewed; of these, 305 were < 50 years old.
  • Younger patients had a significantly higher incidence of adenocarcinoma and large cell carcinoma, and a lower incidence of squamous cell carcinoma.
  • Overall and among surgically treated patients, the survival rates of younger patients with stage 0-I disease were significantly better than those of older patients.
  • Younger patients with early-stage primary lung cancer had a significantly better prognosis than older patients, although survival in the advanced stages was not significantly different.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Large Cell. Carcinoma, Squamous Cell. Lung Neoplasms. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812347.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Ichikawa M, Suzuki R, Kataoka K, Noda Y, Shindoh J, Matsumoto S, Tanikawa Y, Suzuki K, Baba K, Shindo Y, Kondo M, Imaizumi K, Kume H, Hasegawa Y, Takagi K, Taniguchi H: Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study. Lung Cancer; 2010 Sep;69(3):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
  • We conducted a phase II trial to evaluate the safety and efficacy of weekly paclitaxel in patients with resistant or relapsed non-small cell lung cancer (NSCLC) treated with docetaxel and carboplatin.
  • The majority of patients had adenocarcinoma (84%) and stage IV disease (81%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20053476.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


62. Gupta R, Dastane AM, Forozan F, Riley-Portuguez A, Chung F, Lopategui J, Marchevsky AM: Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol; 2009 Jan;22(1):128-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method.
  • Patients with advanced pulmonary adenocarcinoma exhibiting overexpression or mutation of epidermal growth factor receptor tend to respond better to targeted therapy with tyrosine kinase inhibitors such as gefitinib and erlotinib.
  • There is no consensus regarding how these neoplasms should be routinely tested for epidermal growth factor receptor (EGFR) and whether the results of immunohistochemistry (IHC), mutation analysis and fluorescent in situ hybridization correlate with each other or are independent predictive variables.
  • We tested 100 pulmonary adenocarcinomas from patients with stage III or IV disease for EGFR abnormalities using IHC, PCR and fluorescent in situ hybridization (FISH) and compared the results using kappa and other statistical methods.
  • The need to standardize the approach to EGFR testing in patients with advanced pulmonary adenocarcinoma is discussed.
  • [MeSH-major] Adenocarcinoma / metabolism. Immunohistochemistry / standards. In Situ Hybridization, Fluorescence / standards. Lung Neoplasms / metabolism. Polymerase Chain Reaction / standards. Receptor, Epidermal Growth Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997733.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


63. Chakra M, Pujol JL, Lamy PJ, Bozonnat MC, Quantin X, Jacot W, Daurès JP: Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol; 2008 Oct;3(10):1119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
  • INTRODUCTION: High circulating serum vascular endothelial growth factor (VEGF) levels might reflect enhanced angiogenesis in patients suffering from non-small cell lung cancer (NSCLC).
  • RESULTS: Receiver operating characteristic curves (area under the ROC curve: 0.66 +/- 0.05) showed that circulating VEGF serum level did not demonstrate a high sensitivity-specificity relationship, and therefore, demonstrated a low ability to differentiate NSCLC from benign lung diseases.
  • The circulating VEGF distribution differed significantly according to disease stage, nodal status, and performance status (PS), with the highest levels observed in metastatic stage, positive mediastinal nodal status, and poor PS.
  • CONCLUSION: The prognostic information given by a high circulating VEGF serum level is not an independent determinant of survival owing to a high relationship with main prognostic variables such as PS, stage of the disease, and nodal status.
  • This finding does not preclude a putative prognostic impact of in situ detection of VEGF and VEGF receptors in tumor specimen.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Antigens, Neoplasm / blood. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / therapy. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Keratin-19. Keratins / blood. Male. Middle Aged. Phosphopyruvate Hydratase / blood. Prognosis. Prospective Studies. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827607.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


64. Wang XY, Yao Z, Li Y, Liu T, Zheng HY, Zhu CZ, Sun CY, Wang AX, Zhao M, Wu XY: Expression and significance of Survivin mRNA in lung cancer tissue microarray detected by FISH. Chin Med Sci J; 2005 Sep;20(3):214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of Survivin mRNA in lung cancer tissue microarray detected by FISH.
  • OBJECTIVE: To investigate the expression of Survivin mRNA in lung cancer tissue microarray (TMA) by fluorescence in situ hybridization (FISH) method, and determine the role and significance of it in lung cancer genesis and progress.
  • Fifty-four cases of lung cancer and 10 cases of normal lung tissue were examined.
  • RESULTS: Survivin mRNA was expressed in 66.7% (36/54) of lung cancer; the positive ratio of lung cancer was significantly higher than that of normal lung tissue (0/10; chi2 = 15.238, P < 0.05).
  • The positive ratio of Survivin mRNA was significantly higher in stage III-IV(12/13, 92.3%) than stage I - II (24/41, 58.5%; chi2 = 5.066, P < 0.05).
  • CONCLUSION: Survivin mRNA highly expresses in lung cancer, which is related to the progress and malignant behavior.
  • Survivin may play a promoting role in lung cancer genesis and progress and provide a basis for estimating prognosis and treatment.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16261898.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


65. Kwon MS, Shin SH, Yim SH, Lee KY, Kang HM, Kim TM, Chung YJ: CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung. Lung Cancer; 2007 Jul;57(1):46-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung.
  • BACKGROUND: The prognosis of lung cancer is still poor, since there are few early detection tools available yet.
  • PATIENTS AND METHODS: In this study, we observed the expression of CD63 in 90 cases of non-small cell lung cancer (NSCLC) to explore the potential of this molecule as a prognostic biomarker for lung cancer subtypes using real-time quantitative RT-PCR and tissue microarray based immunohistochemistry.
  • CD63 protein negativity was significantly associated with SqCs type, larger tumor size, and advanced stage.
  • This association was also significant in earlier stage (I and II) AdCs (p=0.041), but not in advanced stage AdCs.
  • CONCLUSIONS: Taken together, these results suggest that CD63 can be a biomarker for predicting the prognosis in earlier stage of lung AdCs.
  • Our findings can be a clue to investigate the role of CD63 in tumorigenesis of AdCs of lung and other cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Platelet Membrane Glycoproteins / metabolism
  • [MeSH-minor] Aged. Antigens, CD63. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Microarray Analysis. Middle Aged. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tumor Burden

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350713.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD63; 0 / Biomarkers, Tumor; 0 / CD63 protein, human; 0 / Platelet Membrane Glycoproteins
  •  go-up   go-down


66. Cicenas S, Zaliene A, Atkocius V: [Treatment outcome of locally advanced stage IIIA/B lung cancer]. Medicina (Kaunas); 2009;45(6):452-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcome of locally advanced stage IIIA/B lung cancer].
  • OBJECTIVE: To determine survival of patients with stage IIIA/B non-small cell lung cancer considering disease stage and treatment methods.
  • MATERIAL AND METHODS: A total of 304 patients with non-small cell lung cancer were treated at the Department of Thoracic Surgery and Oncology, Institute of Oncology, Vilnius University, in 2000-2004.
  • Stage IIIA (T3N1-2M0) cancer was diagnosed for 193 (63.5%) patients and stage IIIB (T4N0-1M0) cancer was diagnosed for 111 (36.5%) patients.
  • According to morphology, there were 219 (72%) patients with squamous cell lung cancer, 80 (26.3%) with adenocarcinoma, and 5 (1.7%) patients with large cell carcinoma.
  • Surgery was performed in 145 patients: 84 (57.9%) patients underwent lung resection (T3-4N0-1M0), 51 (35.2%) patients - thoracotomy, and 10 (6.7%) patients - other palliative thoracic procedures (mediastinotomy, pleurectomy, mediastinoscopy).
  • The median and mean survival of patients with stage IIIA cancer was 8.3 months and 10.4 months, respectively, and that of patients with stage IIIB cancer - 6.4 months and 9.0 months, respectively (P < or =0.05).
  • The median survival of the patients with stage IIIA cancer who received a combination of operation, chemotherapy, and radiation therapy with a total dose of >40 Gy was 14.4 months (mean, 14.7 months), and the median survival of those who received operation, chemotherapy, and radiation therapy with a total dose of < or =40 Gy was 9.7 months (mean, 14.1 months); the median survival of the patients who underwent surgery alone was 4.9 months (mean, 6.7 months) (P=0.004 and P=0.007), respectively.
  • There was a significant difference in the median survival comparing the patients with stage IIIB cancer who underwent surgery alone and those who received a combination of radiation therapy and chemotherapy (median survival of 5.0 months [mean, 8.1 months] versus 16.8 months [mean, 17.6 months], respectively; P < or =0.05).
  • CONCLUSIONS: Disease stage had an influence on the survival of patients with non-small cell lung cancer: patients with stage IIIA (T3N0-1M0) cancer without metastases to mediastinal lymph nodes (N factor) survived longer than patients with stage IIIB (T4N1-2M0) cancer, where not only N factor had an impact but T factor as well.
  • Better treatment outcomes, i.e. longer survival, can be achieved when a combination of three treatment types - surgery, chemotherapy, and radiation therapy - is applied to patients with stage IIIA or IIIB non-small cell lung cancer.
  • The patients with stage IIIA disease who received surgery and radiation therapy (total dose, >40 Gy), and combinations of surgery, chemotherapy, and radiation therapy and second-line chemotherapy showed a significantly longer survival than those who received surgery alone.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Antineoplastic Agents / therapeutic use. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Lung / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Radiotherapy Dosage. Thoracotomy. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605965.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


67. Zeng T, Wen J, Li X: [The value and association of CCR7 expression in NSCLC with lymph node metastasis.]. Zhongguo Fei Ai Za Zhi; 2008 Apr 20;11(2):246-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: SABC immunohitochemcal staining was used to investigate the expression of CCR7 by rabbit anti-human CCR7 monoclonal antibody, and the specimens were 17 cases of adenocarcinoma, 17 cases of Squamous cell Carcinoma, 12 cases of Adenosquamous Carcinoma, 4 cases of large cell carcinoma and 28 cases of metastasized lymph nodes of lung cancer.
  • Negative control sections use 5 cases of inflammatory pseudotumor and 20 cases of normal lung tissue.
  • RESULTS: 1.The expression of CCR7 in pulmonary tumor tissue was remarkably higher than normal lung tissue (P <0.005); 2.
  • Along with the increment that clinical stage, the CCR7 expression had increases the high trend (P =0.003).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731910.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ, Lee JS: Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1037-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
  • PURPOSE: For locoregionally advanced inoperable non-small-cell lung cancer (NSCLC), concurrent chemoradiotherapy has become a standard therapy.
  • METHODS AND MATERIALS: Eligibility included inoperable clinical Stage III NSCLC without pleural effusion, ECOG performance status 0-1, and weight loss < or =5%.
  • The median age was 59 years and 13 patients had IIIA and 27 had IIIB; 24 had squamous ca, 12 had adenocarcinoma, and 4 had others.
  • CONCLUSIONS: Induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with etoposide and cisplatin showed very promising survival in patients with Stage III NSCLC, especially in those without supraclavicular nodal involvement, which warrants further evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024178.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


69. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol; 2009 Oct;135(10):1429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.
  • METHODS: A total of 287 patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy were retrospectively analysed regarding long-term medication with ACEI and ARB as well as histological type, stage, performance status, gender, age, dose-intensity of chemotherapy and survival.
  • CONCLUSIONS: Addition of ACEI or ARB to platinum-based first-line chemotherapy may contribute to prolonged survival in patients with advanced lung cancer.
  • [MeSH-major] Angiotensin II Type 1 Receptor Blockers / therapeutic use. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged. Platinum / therapeutic use. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2003 Dec;14(12):3061-71 [14638905.001]
  • [Cites] Mini Rev Med Chem. 2006 Jul;6(7):835-44 [16842133.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):671-9 [8698858.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1247-52 [15785746.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):64-9 [12094630.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1504-13 [14508839.001]
  • [Cites] Am J Med. 2008 Aug;121(8 Suppl):S8-15 [18638617.001]
  • [Cites] Oncologist. 2007 Jun;12(6):713-8 [17602060.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Oct;130(10):567-73 [15449186.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):748-57 [18181094.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6038-45 [14676130.001]
  • [Cites] Ann N Y Acad Sci. 2008 Sep;1138:65-72 [18837885.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4176-9 [12154013.001]
  • [Cites] Trends Endocrinol Metab. 2005 Sep;16(7):293-9 [16061390.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2462-70 [11745304.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):277-88 [18310294.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004569 [17943820.001]
  • [Cites] Chest. 2006 Oct;130(4):1211-9 [17035458.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):370-7 [12811831.001]
  • [Cites] Lancet. 1998 Jul 18;352(9123):179-84 [9683206.001]
  • [Cites] Acta Diabetol. 2005 Apr;42 Suppl 1:S33-41 [15868118.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Semin Oncol. 1988 Dec;15(6 Suppl 7):58-61 [2851181.001]
  • [Cites] J Clin Invest. 2003 Jul;112(1):67-75 [12840060.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):271-9 [15637093.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1633-7 [11337361.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):57-66 [18026817.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 3;100(17):1223-32 [18728281.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):30-6 [15162145.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3601-14 [18728246.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1139-47 [14617787.001]
  • [Cites] Int J Urol. 2008 Jan;15(1):19-26 [18184167.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Jun;35(6):881-900 [12676174.001]
  • [Cites] Am Heart J. 2004 Nov;148(5):747-54 [15523303.001]
  • [Cites] Blood. 2004 Jul 15;104(2):402-8 [15044253.001]
  • (PMID = 19399518.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin-Converting Enzyme Inhibitors; 49DFR088MY / Platinum
  •  go-up   go-down


70. Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C: Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg; 2006 Jun;81(6):1988-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping.
  • BACKGROUND: Adenocarcinoma (AC) is the most common lung cancer, followed by squamous cell carcinoma (SCC).
  • Therefore, we compared subgroups according to presence or not of bronchioloalveolar carcinoma or solid adenocarcinoma with mucin component, or both.
  • RESULTS: Compared with ACs, SCCs had a higher number of males and older patients, and incidences of endobronchial tumors, pneumonectomies, and stage II tumors were higher.
  • The ACs with solid AC with mucin components (n = 239) were characterized by more males and stage IIB patients, and had poorer survival rates (38.6% vs 61.4%; p < 0.0014) than the ACs without solid AC with mucin component.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adenocarcinoma, Bronchiolo-Alveolar / therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / statistics & numerical data. Combined Modality Therapy. Female. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / methods. Pneumonectomy / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant / statistics & numerical data. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731118.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


71. Wang EH, Liu Y, Xu HT, Dai SD, Liu N, Xie CY, Yuan XM: Abnormal expression and clinicopathologic significance of p120-catenin in lung cancer. Histol Histopathol; 2006 08;21(8):841-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal expression and clinicopathologic significance of p120-catenin in lung cancer.
  • The aim of this study was to investigate the relationship between the expression of p120ctn in human lung squamous cell carcinoma, adenocarcinoma and its clinicopathologic significance.
  • The expression of p120ctn in tumors and adjacent normal lung tissues from 143 patients was examined by immunohistochemistry and Western blot.
  • Abnormal expression of p120ctn, including cytoplasmic and reduced membranous expression, was found in 114 of 143 specimens (79.7%) and was significantly associated with poor differentiation, high TNM stage, and lymph node metastasis (P<0.05 for each) but not with histologic subtype.
  • Compared with that in normal lung tissues, membranous protein level was lower in tumors (P=0.003).
  • Abnormal expression of p120ctn is associated with tumor progression and poor prognosis in lung squamous cell carcinoma and adenocarcinoma.
  • Reduced expression or even the absence of p120ctn isoform 1 and 3 in tumor cell membranes may be responsible for the abnormal expression of p120ctn that has been found in lung cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Cell Adhesion Molecules / metabolism. Lung Neoplasms / pathology. Phosphoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Catenins. Female. Humans. Immunoenzyme Techniques. Lung / metabolism. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Protein Isoforms. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691536.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Phosphoproteins; 0 / Protein Isoforms; 0 / delta catenin
  •  go-up   go-down


72. Movsas B, Langer CJ, Ross HJ, Wang L, Jotte RM, Feigenberg S, Xu F, Huang CH, Monberg MJ, Obasaju CK: Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer. J Thorac Oncol; 2010 May;5(5):673-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
  • PURPOSE: Southwest Oncology Group 9504 demonstrated the feasibility and potential benefit of docetaxel consolidation after etoposide, cisplatin, and radiotherapy in patients with locally advanced non-small cell lung cancer.
  • METHODS: Patients with stage III non-small cell lung cancer and good performance status were included.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / therapy. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354453.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


73. Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, Kang CH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Kim YW, Kim JH, Heo DS, Bang YJ: Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol; 2010 Mar;5(3):320-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
  • BACKGROUND: We analyzed the significance of class III beta-tubulin (TUBB3) expression in curatively resected non-small cell lung cancer as a prognostic marker along with previously reported excision repair cross complementation group 1 (ERCC1).
  • RESULTS: Sixty percent of patients had stage I disease, 17% stage II, 18% stage IIIA, and 5% stage IIIB.
  • A multivariate analysis that incorporated covariates including TUBB3 expression, age, stage, EGFR mutation status, histology, and ERCC1 expression showed that TUBB3 was an independent unfavorable prognostic factor for OS (hazard ratio 2.083; p = 0.008) and relapse free survival (hazard ratio 1.978; p = 0.020).
  • CONCLUSIONS: TUBB3 expression is an independent unfavorable prognostic marker in patients with curatively resected non-small cell lung cancer who did not receive adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Tubulin / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. DNA Repair. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087230.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / TUBB3 protein, human; 0 / Tubulin; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  •  go-up   go-down


74. Suga Y, Miyajima K, Oikawa T, Maeda J, Usuda J, Kajiwara N, Ohira T, Uchida O, Tsuboi M, Hirano T, Kato H, Ikeda N: Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer. Oncol Rep; 2008 Nov;20(5):1137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer.
  • Inactivation of the p16 and ESR1 tumor suppressor genes by promoter lesion methylation has been reported in many tumor types, including lung cancer.
  • We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR.
  • For both genes, there was a statistically significant difference in the methylation ratio between non-small cell lung cancer patients and controls (p16; p<0.01, ESR1; p<0.001).
  • Moreover in Stage I cases, the methylation positive rate of each gene (p16, ESR1 and p16 or ESR1) was higher than the CEA positive rate (p<0.05, p<0.001, p<0.001).
  • Evaluation of p16 and ESR1 promoter methylation in blood using real-time PCR appears to be very useful for lung cancer diagnosis and there is some possibility that these methylated genes might come to represent useful biomarkers for the early detection of lung cancer.
  • Our study results also suggested that comparative evaluation of the methylation ratio before and after surgery might be a powerful tool to predict the prognosis of lung cancer patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. DNA Methylation. Estrogen Receptor alpha / genetics. Genes, p16. Lung Neoplasms / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949413.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / estrogen receptor alpha, human
  •  go-up   go-down


75. Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH: CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol; 2010 May;5(5):649-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
  • However, the importance of the CD24 in non-small cell lung carcinomas (NSCLCs) has not been elucidated well.
  • RESULTS: CD24-high expression was demonstrated in 87 of 267 (33%) and was associated with adenocarcinoma (ADC) histology than in squamous cell carcinoma histology (64 of 165 [39%] vs. 20 of 88 [23%]; p = 0.023).
  • CD24-high expression had a tendency to correlate with new pathologic stage (p-stage) (p = 0.089) rather than old p-stage (p = 0.253).
  • Performance status and new p-stage, regardless of the tumor histology, were identified as consistent independent prognostic factors of disease progression and cancer-related death.
  • Performance status and new p-stage, to a lesser extent, age correlated with progression-free survival and cancer-specific survival, regardless of tumor histology.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD24 / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biomark Med. 2010 Aug;4(4):495 [20701438.001]
  • (PMID = 20354454.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor; 0 / CD24 protein, human
  •  go-up   go-down


76. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX: Outcomes with esophageal cancer radiation therapy. J Thorac Oncol; 2009 Jul;4(7):880-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Men make up 75% or more of the patients with esophageal cancer, most patients have adenocarcinoma in the gastroesophageal junction, and almost 75% have stage II or III disease.
  • CONCLUSION: Although fully delineated comparisons must await incorporation and study of data through 2007, this analysis suggests that multimodality management that has been adapted in recent years may be associated with the improvements in outcomes of these cases of largely stage II and III esophageal adenocarcinoma found at the gastroesophageal junction.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458557.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Stevenson M, Mostertz W, Acharya C, Kim W, Walters K, Barry W, Higgins K, Tuchman SA, Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. Clin Cancer Res; 2009 Dec 15;15(24):7553-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • EXPERIMENTAL DESIGN: Lung cancer cell lines with corresponding gene expression data and genes associated with an embryonic stem cell identity were used to develop a signature of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early-stage (I-IIIa) lung adenocarcinoma data sets with clinically annotated gene expression data.
  • Lung tumors (n = 569) and adenocarcinoma cell lines (n = 31) expressing the ES phenotype were more likely to be resistant to cisplatin (P < 0.0001 and P = 0.006, respectively).
  • CONCLUSIONS: Lung adenocarcinomas that share a common gene expression pattern with normal human embryonic stem cells were associated with decreased survival, increased biological complexity, and increased likelihood of resistance to cisplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Clin Cancer Res 2009;15(24):7553-61)
  • [CommentIn] NIH Guide Grants Contracts. 2015 Nov 20;:NOT-OD-16-021 [26601329.001]
  • [RetractionIn] Stevenson M, Mostertz W, Acharya CR, Kim W, Walters K, Barry W, Higgins K, Tuchman SA, Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A. Clin Cancer Res. 2012 Mar 15;18(6):1818 [22355011.001]
  • (PMID = 19996213.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA131049
  • [Publication-type] Journal Article; Retracted Publication
  • [Publication-country] United States
  •  go-up   go-down


78. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol; 2008 Jul 20;26(21):3543-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
  • PURPOSE: Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: This noninferiority, phase III, randomized study compared the overall survival between treatment arms using a fixed margin method (hazard ratio [HR] < 1.176) in 1,725 chemotherapy-naive patients with stage IIIB or IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 1.
  • Overall survival was statistically superior for cisplatin/pemetrexed versus cisplatin/gemcitabine in patients with adenocarcinoma (n = 847; 12.6 v 10.9 months, respectively) and large-cell carcinoma histology (n = 153; 10.4 v 6.7 months, respectively).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


79. Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, Cozen W, Hagen JA, Koss MN, Laird-Offringa IA: Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer; 2007;6:70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma.
  • BACKGROUND: Lung cancer is the number one cancer killer of both men and women in the United States.
  • Three quarters of lung cancer patients are diagnosed with regionally or distantly disseminated disease; their 5-year survival is only 15%.
  • DNA hypermethylation at promoter CpG islands shows great promise as a cancer-specific marker that would complement visual lung cancer screening tools such as spiral CT, improving early detection.
  • In lung cancer patients, such hypermethylation is detectable in a variety of samples ranging from tumor material to blood and sputum.
  • We used the real-time PCR-based method MethyLight to examine DNA methylation quantitatively at twenty-eight loci in 51 primary human lung adenocarcinomas, 38 adjacent non-tumor lung samples, and 11 lung samples from non-lung cancer patients.
  • RESULTS: We identified thirteen loci showing significant differential DNA methylation levels between tumor and non-tumor lung; eight of these show highly significant hypermethylation in adenocarcinoma: CDH13, CDKN2A EX2, CDX2, HOXA1, OPCML, RASSF1, SFPR1, and TWIST1 (p-value << 0.0001).
  • Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67-86% and specificity of 74-82%.
  • DNA methylation of these loci did not differ significantly based on gender, race, age or tumor stage, indicating their wide applicability as potential lung adenocarcinoma markers.
  • We applied random forests to determine a good classifier based on a subset of our loci and determined that combined use of the same four top markers allows identification of lung cancer tissue from non-lung cancer tissue with 94% sensitivity and 90% specificity.
  • CONCLUSION: The identification of eight CpG island loci showing highly significant hypermethylation in lung adenocarcinoma provides strong candidates for evaluation in patient remote media such as plasma and sputum.
  • The four most highly ranked loci, CDKN2A EX2, CDX2, HOXA1 and OPCML, which show significant DNA methylation even in stage IA tumor samples, merit further investigation as some of the most promising lung adenocarcinoma markers identified to date.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1837-41 [10760760.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2473-6 [10811126.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] J Natl Cancer Inst. 2001 Oct 3;93(19):1465-72 [11584062.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):291-7 [11895880.001]
  • [Cites] Oncogene. 2002 May 16;21(22):3659-62 [12032868.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):98-104 [12629062.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4128-33 [12821947.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):337-43 [12819783.001]
  • [Cites] Carcinogenesis. 2003 Dec;24(12):1897-901 [12970072.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):23-32 [15013580.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):771-4 [15266335.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):707-17 [15343277.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6119-25 [15447998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(9):3294-8 [2159143.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1169-73 [1311082.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Cell Growth Differ. 1994 Oct;5(10):1033-40 [7848904.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):547-51 [15706431.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):400-5 [15578700.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2566-74 [15852359.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):6823-36 [16326863.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3338-44 [16540689.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] JAMA. 2007 Mar 7;297(9):953-61 [17341709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]
  • [Cites] Int J Cancer. 2007 Sep 15;121(6):1219-26 [17534889.001]
  • [Cites] Lung Cancer. 2007 Nov;58(2):220-30 [17659810.001]
  • (PMID = 17967182.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA119029; United States / NCI NIH HHS / CA / R21 CA102247
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / GPI-Linked Proteins; 0 / H-cadherin; 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / OPCML protein, human; 0 / RASSF1 protein, human; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / Twist Transcription Factor; 0 / homeobox A1 protein
  • [Other-IDs] NLM/ PMC2206053
  •  go-up   go-down


80. Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, Shih JY, Lee YC, Yang PC: Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J; 2008 Oct;32(4):924-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma.
  • Malignant pleural effusions (MPEs) are often observed in lung cancer, especially adenocarcinoma.
  • Epidermal growth factor receptor (EGFR) gene mutations are usually detected in lung adenocarcinoma.
  • The purpose of the present study was to investigate the EGFR mutation rate in MPEs of lung adenocarcinoma.
  • Between June 2005 and December 2006, 136 MPEs from lung adenocarcinoma were collected for EGFR mutation detection.
  • In addition, between April 2001 and November 2004, 91 surgically resected specimens of lung adenocarcinoma from patients without MPEs were assessed for EGFR mutation.
  • The EGFR mutation rate in patients with MPEs was not associated with sex, smoking history, age or cancer stage.
  • By multivariate analysis, an age of <65 yrs, never smoking, Eastern Cooperative Oncology Group performance status 0-1, and EGFR mutation were significantly associated with a longer overall survival for lung adenocarcinoma patients with MPEs.
  • The patients with malignant pleural effusions related to lung adenocarcinoma had a higher epidermal growth factor receptor gene mutation rate than the patients from whom surgically resected specimens were taken.
  • Epidermal growth factor receptor tyrosine kinase inhibitors may be the treatment of choice for lung adenocarcinoma with malignant pleural effusions in east Asia.
  • [MeSH-major] Adenocarcinoma / genetics. Lung Neoplasms / genetics. Mutation. Pleural Effusion / genetics. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508816.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


81. Gu AK, Sun LN, Chen ZL, Zhan ZL, Li JW: [Expression of coxsackievirus and adenovirus receptor in non-small cell lung cancer and its significance]. Zhonghua Zhong Liu Za Zhi; 2009 Apr;31(4):278-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of coxsackievirus and adenovirus receptor in non-small cell lung cancer and its significance].
  • OBJECTIVE: To investigate the mRNA and proten expression of coxsackievirus and adenovirus receptor (CAR) in the corresponding normal lung tissue, para-neoplastic tissue and lung cancer tissue, and the correlation of CAR expression with the carcinogenesis as well as the expression difference in various clinicopathologic parameters.
  • METHODS: The expression of CAR mRNA and protein in the samples from 32 lung cancer patients was determined by RT-PCR and Western blot, respectively.
  • RESULTS: The expression level of CAR mRNA and protein in normal lung tissue, paraneoplastic tissue and cancer tissue were 1.000 +/- 0.012, 1.048 +/- 0.035, 1.282 +/- 0.072, and 0.902 +/- 0.038, 0.944 +/- 0.042, 1.08 +/- 0.052, respectively, with a statistical significance among the groups (P = 0.022, P = 0.007, P = 0.009, P = 0.027).
  • However, there was no statistical significance in other clinicopathologic parameters (P > 0.05), including gender, age, smoking or not, tumor size, with or without lymph node metastasis and TNM stage.
  • It may become a new potential prognostic marker for lung cancer patients.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Receptors, Virus / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Coxsackie and Adenovirus Receptor-Like Membrane Protein. Female. Humans. Lung / metabolism. Lymphatic Metastasis. Male. Middle Aged. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615283.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLMP protein, human; 0 / Coxsackie and Adenovirus Receptor-Like Membrane Protein; 0 / RNA, Messenger; 0 / Receptors, Virus
  •  go-up   go-down


82. Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang LE, Yuan X, O'Reilly MS, Komaki R, Liao Z: Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer; 2010 Aug 16;10:431
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.
  • BACKGROUND: Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer.
  • We hypothesized that VEGF polymorphisms may affect survival outcomes among locally advanced non-small cell lung cancer (LA-NSCLC) patients.
  • RESULTS: Gender, Karnofsky's performance scores (KPS) and clinical stage seemed to influence the OS.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):898-901 [17289883.001]
  • [Cites] J Surg Oncol. 2006 Dec 1;94(7):624-30 [17111394.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):1147-55 [17287073.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):62-6 [18172253.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):612-7 [18223238.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):856-62 [18281657.001]
  • [Cites] Mol Carcinog. 2009 Jun;48(6):563-9 [19009560.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3370-8 [19380441.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4680-5 [19584152.001]
  • [Cites] Pharmacogenomics. 2009 Aug;10(8):1277-83 [19663672.001]
  • [Cites] Cancer Sci. 2009 Oct;100(10):1917-22 [19594543.001]
  • [Cites] Mol Cancer Ther. 2009 Sep;8(9):2496-508 [19755511.001]
  • [Cites] Clin Lung Cancer. 2010 Mar 1;11(2):82-90 [20199973.001]
  • [Cites] Gynecol Oncol. 2010 Apr;117(1):109-16 [20056267.001]
  • [Cites] Pharmacogenomics J. 2011 Jun;11(3):227-36 [20531372.001]
  • [Cites] Cytokine. 2000 Aug;12(8):1232-5 [10930302.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):475-83 [11102890.001]
  • [Cites] J Vasc Res. 2000 Nov-Dec;37(6):443-8 [11146397.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):72-9 [11206229.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):812-6 [12591731.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):452-8 [7844608.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3188-94 [10506617.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):571-5 [15767331.001]
  • [Cites] Lung. 2005 Jan-Feb;183(1):29-42 [15793665.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3647-53 [15897560.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5015-9 [15958542.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1030-6 [17426061.001]
  • (PMID = 20712888.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA131274; United States / NIEHS NIH HHS / ES / R01 ES011740; United States / NCI NIH HHS / CA / R01 CA 131274; United States / NCI NIH HHS / CA / P30 CA 16672; United States / NIEHS NIH HHS / ES / R01 ES11740
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2939547
  •  go-up   go-down


83. Zhao L, Ji W, Zhang L, Ou G, Feng Q, Zhou Z, Lei M, Yang W, Wang L: Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer. J Thorac Oncol; 2010 Apr;5(4):521-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer.
  • INTRODUCTION: We hypothesized that plasma transforming growth factor-beta1 (TGF-beta1) level and its dynamic change are correlated with the prognosis of locally advanced non-small cell lung cancer (NSCLC) treated with radiation therapy (RT).
  • METHODS: Patients with stage IIIA or IIIB NSCLC treated with RT with or without chemotherapy were eligible for this study.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / blood. Lung Neoplasms / radiotherapy. Transforming Growth Factor beta1 / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20130485.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


84. Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M: Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. Tumori; 2008 May-Jun;94(3):398-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
  • AIMS AND BACKGROUND: The aim of this study was to evaluate the relationship between a panel of biological markers (p53, Bcl-2, HER-2, Ki67, DNA ploidy and S-phase fraction) and clinical-pathological parameters and its impact on outcome in non-small cell lung cancer (NSCLC).
  • Median age was 66 years (range, 31-84 years), male/female ratio 117/19, ECOG performance status 0/1 127/4, stage I/II/III 76/25/35, squamous/adenocarcinoma/large-cell/mixed histology 62/49/17/8, smokers yes/no 121/11.
  • Statistically significant associations between high Ki67 and poorly differentiated tumors (P = 0.016) and a smoking history (P = 0.053); p53 positivity and high Ki67 (P = 0.002); HER-2 positivity and adenocarcinoma subtype (P = 0.015) and presence of lymph node involvement (P = 0.006); and Bcl-2 positivity and squamous cell carcinoma subtype (P = 0.058) were observed.
  • After adjusting for stage, none of the examined immunocytochemical markers emerged as an independent factor for disease-free and overall survival; only pathological stage was identified as an independent prognostic factor for disease-free survival (P = 0.0001) and overall survival (P = 0.0001).
  • In the group of 76 patients classified as TNM stage I, high Ki67 was the only marker associated with recurrence of disease (P = 0.05).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Non-Small-Cell Lung / pathology. DNA, Neoplasm / analysis. Flow Cytometry. Lung Neoplasms / chemistry. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / chemistry. Carcinoma, Large Cell / genetics. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / genetics. Female. Humans. Immunohistochemistry. Italy. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Staging. Ploidies. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis


85. Said R, Terjanian T, Taioli E: Clinical characteristics and presentation of lung cancer according to race and place of birth. Future Oncol; 2010 Aug;6(8):1353-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and presentation of lung cancer according to race and place of birth.
  • This study compares the clinical presentation and characteristics of lung cancer among white and black patients according to place of birth, and correlates these factors to outcome.
  • All newly diagnosed lung cancers from 2005 to 2007 in three tertiary medical centers were retrospectively reviewed; 767 patients were identified, 252 of whom were black.
  • Age, sex, family history, place of birth, smoking history, insurance status, clinical stage, histology, grade of differentiation, symptoms, circumstance of diagnosis, treatment and outcome data were retrieved from medical charts.
  • Lung cancer was diagnosed incidentally in 28.2% of white individuals versus 12.3% in black individuals (p < 0.0001).
  • The differences in lung cancer survival could be related to access to care, environmental factors and the biology of the disease.
  • [MeSH-major] African Americans / statistics & numerical data. European Continental Ancestry Group / statistics & numerical data. Health Services Accessibility. Lung Neoplasms / ethnology. Lung Neoplasms / pathology. Residence Characteristics / statistics & numerical data
  • [MeSH-minor] Adenocarcinoma / ethnology. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Aged. Carcinoma, Large Cell / ethnology. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / therapy. Carcinoma, Squamous Cell / ethnology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Small Cell Lung Carcinoma / ethnology. Small Cell Lung Carcinoma / secondary. Small Cell Lung Carcinoma / therapy. Survival Rate


86. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol; 2005 Apr 10;23(11):2544-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
  • Additionally, both agents have demonstrated benefit in patients with previously treated non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: A phase I/II study in two centers examined erlotinib and bevacizumab (A+T) in patients with nonsquamous stage IIIB/IV NSCLC with > or = one prior chemotherapy.
  • ResultsForty patients were enrolled and treated in this study (34 patients at phase II dose); the median age was 59 years (range, 36 to 72 years), 21 were female, 30 had adenocarcinoma histology, nine were never-smokers, and 22 had > or = two prior regimens (three patients had > or = four prior regimens).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


87. Yuki T, Sakuma T, Ohbayashi C, Yoshimura M, Tsubota N, Okita Y, Okada M: Pleomorphic carcinoma of the lung: a surgical outcome. J Thorac Cardiovasc Surg; 2007 Aug;134(2):399-404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic carcinoma of the lung: a surgical outcome.
  • OBJECTIVES: Pleomorphic carcinoma of the lung, a rare malignant disease with a dual-cell component of spindle and/or giant cells, and of epithelial cells, was defined in the World Health Organization classification updated in 1999.
  • Epithelial components were adenocarcinoma in 25 (55.6%) patients, squamous cell carcinoma in 8 (17.8%) patients, and large call carcinoma in 12 (26.7%) patients.
  • CONCLUSIONS: Pulmonary pleomorphic carcinoma, which often presented in symptomatic male smokers as a large peripheral lesion, carried a poor prognosis, even when early-stage disease was diagnosed and resected.
  • [MeSH-major] Carcinoma / surgery. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662779.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Decaluwé H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, Coosemans W, Lerut T: Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg; 2009 Sep;36(3):433-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
  • OBJECTIVE: Analysis of single centre results and identification of prognostic factors of surgical combined modality treatment in pathological proven stage IIIA-N2 non-small cell lung cancer (NSCLC).
  • Adenocarcinoma and squamous cell carcinomas were equally present (48% vs 43%).
  • CONCLUSIONS: Surgery after induction chemotherapy for stage IIIA-N2 NSCLC can be performed with an acceptable mortality and morbidity.
  • Baseline single level N2 disease is an independent prognostic factor for long-term survival.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2009 Sep;36(3):431-2 [19524447.001]
  • (PMID = 19502079.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Choi N, Son DS, Song I, Lee HS, Lim YS, Song MS, Lim DS, Lee J, Kim H, Kim J: RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. Int J Cancer; 2005 Jul 1;115(4):575-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
  • Aberrant methylation of several tumor suppressor genes often occurs during the pathogenesis of lung cancer.
  • RASSF1A is one of the tumor suppressor genes, and it is frequently inactivated by hypermethylation of its promoter region in a variety of human cancers, including lung cancer.
  • It has recently been suggested that RASSF1A methylation was frequently observed in poorly differentiated tumors, and that it was correlated with adverse survival in lung adenocarcinoma (Tomizawa Y, et al., Clin Cancer Res 2002;8:2362-8).
  • In this study, we investigated the pathogenetic and clinicopathologic significance of RASSF1A methylation for the development and/or progression of non small cell lung cancer (NSCLC).
  • However, there was no association between RASSF1A methylation and the individual clinicopathologic features: TNM stage (p > 0.1), recurrence (p > 0.1), lymphatic permeation (p > 0.1) and smoking duration time (p > 0.1).
  • As a result, the stage proved to be the most important factor (p = 0.0089), more than any other factors such as age, gender, cell type, methylation status, differentiation, smoking duration time, tumor size and lymph node permeation.
  • There was no other significant factor other than stage and age.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15700308.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


90. Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Takenaka A, Nakayama T, Yoneda G: Prognostic value of intraoperative pleural lavage cytology for lung cancer without carcinomatous pleuritis: importance in patients with early stage disease during long-term follow-up. Eur J Cardiothorac Surg; 2009 Feb;35(2):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of intraoperative pleural lavage cytology for lung cancer without carcinomatous pleuritis: importance in patients with early stage disease during long-term follow-up.
  • PURPOSE: The clinical significance of intraoperative pleural lavage cytology (PLC) for lung cancer has been insufficiently elucidated.
  • We therefore reviewed the surgical results of lung cancer patients without carcinomatous pleuritis followed up over the long term to elucidate PLC implications.
  • PATIENTS AND METHODS: PLC was performed immediately after thoracotomy in consecutive lung cancer patients without carcinomatous pleuritis undergoing tumor resection between 1988 and 1997.
  • RESULTS: Eighty-nine (13.1%) of 679 patients had positive PLC findings, which were observed more frequently in patients with advanced stage, larger tumor size, higher involvement of the pleura, lymph node, lymphatics and vessels.
  • Among 395 patients with stage I disease, 35 (8.9%) showed PLC-positive findings, and their overall survival rate was significantly poor compared with those with PLC-negative findings (p<0.0001).
  • In contrast, such differences were not observed among patients with more advanced stage diseases.
  • In regard to histological type, a difference in the postoperative survival rate according to PLC status was statistically found in adenocarcinoma type (p<0.0001), but not in squamous cell carcinoma type (p=0.24).
  • According to multivariate analysis, PLC was an independent prognostic factor for all tested patients (p=0.007, hazard ratio=0.60) as well as for those with stage I disease (p=0.0135, hazard ratio=0.51).
  • Interestingly, late pleural recurrence more than 5 years occurred in five (5.6%) of PLC-positive patients, all of whom were included in stage I.
  • CONCLUSIONS: Based on the present analysis of long-term follow-up after operation, PLC may also be an independent prognostic factor.
  • In particular, the PLC status of patients with stage I disease or adenocarcinoma type has an important impact on survival.
  • For PLC-positive patients with stage I disease, careful serial follow-up for more than 5 years is required while paying attention to late pleural recurrence.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Pleural Cavity / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041255.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA: Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol; 2006 Jan 10;24(2):306-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.
  • PURPOSE: Akt is a serine/threonine kinase that has been implicated in lung tumorigenesis and lung cancer therapeutic resistance.
  • Full activation of Akt requires two phosphorylation events, but only one site of phosphorylation (S473) has been evaluated thus far in clinical non-small-cell lung cancer (NSCLC) specimens, which has resulted in conflicting results regarding the prognostic significance of Akt activation in NSCLC.
  • PATIENTS AND METHODS: Phosphospecific antibodies against T308 and S473 were validated and used in an immunohistochemical analysis of tissue microarray slides containing NSCLC specimens (n = 300) and surrounding lung tissue specimens (n = 100).
  • When Akt activation was defined by using both sites of phosphorylation, Akt activation was specific for NSCLC tumors versus surrounding tissue (73.4% v 0%; P < .05), was higher in adenocarcinoma than in squamous cell carcinoma (78.1% v 68.5%; P = .040), and was associated with shorter overall survival for all stages of disease (log-rank P = .041).
  • In multivariate analyses, increased phosphorylation of T308 alone was a poor prognostic factor for stage I patients or for tumors < 5 cm (log-rank P = .011 and P = .015, respectively).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / metabolism. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Phosphorylation. Prognosis


92. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC, Yang PC: Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer; 2005 Jul 1;115(4):545-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
  • After stratification by disease stage or histologic subtype, the prognostic significance of high total COX-2 mRNA expression was still apparent in both stage I and stage II-IV and in both squamous cell carcinoma and adenocarcinoma (p < or = 0.01 for all).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Prostaglandin-Endoperoxide Synthases / genetics. RNA, Messenger / genetics. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Aged. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Cyclooxygenase 2. Female. Humans. Male. Membrane Proteins. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / enzymology. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15704107.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


93. Kim HR, Kim DJ, Lee WW, Jheon S, Sung SW: The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma. Eur J Cardiothorac Surg; 2009 Apr;35(4):712-6; discussion 716-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma.
  • OBJECTIVE: Positron emission tomography has proven to be an invaluable tool for diagnosing and staging non-small cell lung cancer.
  • The authors analyzed relationships between the preoperative maximum standardized uptake values (SUVmax) of masses and early recurrence rates in patients with stage I pulmonary adenocarcinoma.
  • METHODS: One hundred and seven patients with stage I pulmonary adenocarcinoma who underwent curative resection between September 2003 and June 2007 were enrolled in this study.
  • RESULTS: At diagnosis 57 patients had stage Ia disease and 50 stage Ib disease.
  • Our findings indicate that even in stage I adenocarcinoma patients, mass size and SUVmax are related to higher rates of recurrence, and thus, these patients require more attentive observation after curative resection.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Lung Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211260.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


94. Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL, Stass SA, Jiang F: Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene; 2006 Apr 27;25(18):2628-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach.
  • We used a functional genomic approach that integrated simultaneous genomic and transcript microarray, proteomics, and tissue microarray analyses to directly identify putative oncogenes in lung adenocarcinoma.
  • We first identified 183 genes with increases in both genomic copy number and transcript in six lung adenocarcinoma cell lines.
  • Parallel fluorescence in situ hybridization and immunohistochemical analyses of EEF1A2 and KCIP-1 in tissue microarrays from patients with lung adenocarcinoma showed that gene amplification was associated with high protein expression for both genes and that protein overexpression was related to tumor grade, disease stage, Ki-67 expression, and a shorter survival of patients.
  • The amplification of EEF1A2 and KCIP-1 and the presence of overexpressed protein in tumor samples strongly suggest that these genes could be oncogenes and hence potential targets for diagnosis and therapy in lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Neoplasm Proteins / genetics. Oncogenes / genetics
  • [MeSH-minor] Electrophoresis, Gel, Two-Dimensional. Gene Amplification. Gene Dosage. Gene Expression Profiling. Genomics. Humans. In Situ Hybridization, Fluorescence. Oligonucleotide Array Sequence Analysis. Peptide Elongation Factor 1 / antagonists & inhibitors. Peptide Elongation Factor 1 / genetics. Peptide Elongation Factor 1 / metabolism. RNA, Small Interfering / genetics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Tissue Array Analysis. Tumor Cells, Cultured


95. Shanmugam C, Jhala NC, Katkoori VR, Wan W, Meleth S, Grizzle WE, Manne U: Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer; 2010 Aug 01;116(15):3577-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who had early stage tumors (stages I and II) with high MUC4 expression had a shorter disease-specific survival (log-rank; P=.007) than patients who had with low expression.
  • Patients who had advanced-stage CRCs (stages III and IV) did not demonstrate such a difference (log-rank; P=.108).
  • Multivariate regression models that were generated separately for patients with early stage and advanced-stage CRC confirmed that increased expression of MUC4 was an independent indicator of a poor prognosis only for patients who had early stage CRCs (hazard ratio, 3.77; 95% confidence interval, 1.46-9.73).
  • CONCLUSIONS: The current results indicated that increased MUC4 expression is a predictor of poor survival in CRC, specifically for patients who have early stage tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • [Cites] Gastroenterology. 1994 Apr;106(4):1054-61 [8143972.001]
  • [Cites] Cancer Res. 1992 Nov 1;52(21):5971-8 [1394223.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9 [8683636.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):560-4 [8813954.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):346-58 [9221816.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1063-74 [10424891.001]
  • [Cites] Cancer. 2005 May 15;103(10):2163-70 [15816050.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):881-9 [15958852.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):845-52 [16049287.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):593-8 [17425390.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] Eur J Clin Invest. 2007 May;37(5):416-24 [17461988.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):345-57 [17595659.001]
  • [Cites] J Histochem Cytochem. 2008 Mar;56(3):305-12 [18071066.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):1048-56 [18397823.001]
  • [Cites] FASEB J. 2008 Aug;22(8):3035-45 [18492726.001]
  • [Cites] Oncol Rep. 2009 Jan;21(1):49-56 [19082442.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):344-51 [19127263.001]
  • [Cites] Dig Dis. 1999;17(2):67-79 [10545712.001]
  • [Cites] Histopathology. 2000 Feb;36(2):121-6 [10672056.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4017-25 [11051251.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):461-70 [11313977.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4033-40 [11751498.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):150-7 [14657954.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Head Neck. 2004 Apr;26(4):353-64 [15054739.001]
  • [Cites] Laryngoscope. 2004 Aug;114(8 Pt 2 Suppl 101):1-32 [15284539.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):953-64 [7657125.001]
  • (PMID = 20564074.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NCI NIH HHS / CA / 2U54-CA118948-03; United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / U24-CA086359; United States / NCI NIH HHS / CA / R01-CA98932-01; United States / NCI NIH HHS / CA / R03-CA139629-01; United States / NCI NIH HHS / CA / R03 CA139629; United States / NCI NIH HHS / CA / R03 CA139629-01; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-4
  • [Other-IDs] NLM/ NIHMS189749; NLM/ PMC2910814
  •  go-up   go-down


96. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS, Lu MC, Feng AC: Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor? Lung Cancer; 2009 Nov;66(2):262-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?
  • BACKGROUND: Women with non-small cell lung cancer (NSCLC) appear to have better survival.
  • Demographics, histology, and disease stage between sexes were compared.
  • The clinical prognostic factors to be analyzed in addition to gender included stage, age, smoking history and histology.
  • RESULTS: Of the 738 patients, 695 were analyzed with a definite stage (94.2%; 315 females and 380 males), which was similar in both sexes.
  • Females were younger (median age: 59.5 years vs. 65.0 years; P<0.001) and more likely to have adenocarcinoma (81% vs. 60.5%; P<0.001).
  • Patients with earlier stage, younger patients, never-smokers and females had better overall survival in univariate analyses and no significant survival difference was noted between adenocarcinoma and squamous cell carcinoma.
  • Subgroup analyses revealed the survival of never-smoker males with adenocarcinoma was similar to that of females.
  • Never-smokers with adenocarcinoma should be given special attention regardless of sex as they imply better survival with different treatment outcomes.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / mortality. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / mortality. Female. Humans. Male. Middle Aged. Prognosis. Sex Factors. Smoking


97. Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM: Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol; 2009 May;4(5):578-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
  • This study investigates the prognostic impact of FGF2 and FGFR-1 in tumor cells and tumor stroma of resected non-small cell lung carcinomas (NSCLC) and explores the importance of their coexpression with VEGFR-3 or PDGF-B.
  • METHODS: Tumor tissue samples from 335 resected patients with stage I to IIIA NSCLC were obtained and tissue microarrays were constructed from duplicate cores of tumor cells and tumor-related stroma from each specimen.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Fibroblast Growth Factor 2 / metabolism. Lung Neoplasms / metabolism. Proto-Oncogene Proteins c-sis / metabolism. Vascular Endothelial Growth Factor Receptor-3 / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Receptor, Fibroblast Growth Factor, Type 1 / metabolism. Retrospective Studies. Stromal Cells / metabolism. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318994.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-sis; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


98. Lee MK, Kim JH, Lee CH, Kim JM, Kang CD, Kim YD, Choi KU, Kim HW, Kim JY, Park DY, Sol MY: Clinicopathological significance of BGP expression in non-small-cell lung carcinoma: relationship with histological type, microvessel density and patients' survival. Pathology; 2006 Dec;38(6):555-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of BGP expression in non-small-cell lung carcinoma: relationship with histological type, microvessel density and patients' survival.
  • This study was performed to investigate BGP expression in non-small-cell lung carcinoma (NSCLC).
  • BGP expression did not correlate with patient age or tumour stage, but was more frequent in females than males.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / blood supply. Carcinoma, Non-Small-Cell Lung / pathology. Glycogen Phosphorylase, Brain Form / metabolism. Lung Neoplasms / blood supply. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Lung / blood supply. Lung / metabolism. Lung / pathology. Male. Microcirculation. Middle Aged. Prognosis. Sex Characteristics. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393985.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.4.1.- / Glycogen Phosphorylase, Brain Form
  •  go-up   go-down


99. Tanioka M, Katsumata N, Sasajima Y, Ikeda S, Kato T, Onda T, Kasamatsu T, Fujiwara Y: Clinical characteristics and outcomes of women with stage IV endometrial cancer. Med Oncol; 2010 Dec;27(4):1371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcomes of women with stage IV endometrial cancer.
  • Treatment strategies for patients with stage IV endometrial cancer (EC) remain controversial.
  • We retrospectively analyzed the clinical characteristics and outcomes of 41 women with stage IV EC.
  • The results of preoperative cytologic evaluation and biopsy of the endometrium were reviewed by a single pathologist for patients in whom stage IV EC was diagnosed preoperatively.
  • Of the 41 patients with stage IV EC (median age, 62 years), 31 had surgical stage IV disease and 10 had clinical stage IV disease.
  • Twenty-eight patients were diagnosed of stage IV EC before surgery or without surgery.
  • Neither surgery as primary therapy nor optimal cytoreduction was significantly related to overall survival in either the 28 patients in whom stage IV was diagnosed preoperatively or in all 41 patients.
  • In women with stage IV EC, histologic features and extent of disease are more important determinants of outcomes than any kind of treatment.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):4-9 [14751130.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):85-91 [10926785.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):285-91 [17688923.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):56-60 [9345357.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):448-53 [12366661.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):325-33 [17532033.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):10-4 [14751131.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):237-40 [8314145.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):133-8 [15385122.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):345-52 [15099944.001]
  • (PMID = 20024630.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, Cantonati H, Attems J, Gsur A, Micksche M: Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol; 2005 Jun;131(6):355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
  • PURPOSE: The aim of this retrospective study was to comparatively investigate the expression of the three drug-resistance genes P-glycoprotein (P-gp), multidrug-resistance protein 1 (MRP1), and lung resistance protein (LRP), in non-small cell lung cancer (NSCLC) tissues, and to assess possible associations with clinicopathologic features.
  • A weak association was observed between higher grading and P-glycoprotein expression (p <0.08) as well as lower grading and MRP1 expression in the case of adenocarcinoma (p <0.05).
  • MRP1 levels were highest in TNM stage I and declined with advanced stage (p <0.03).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Drug Resistance, Multiple. Lung Neoplasms / metabolism. Neoplasm Proteins / metabolism. P-Glycoprotein / metabolism. P-Glycoproteins / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Antineoplastic Combined Chemotherapy Protocols. Bronchi / metabolism. Bronchi / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2279-89 [9748150.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):550-4 [7669560.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):27-36 [12125964.001]
  • [Cites] Science. 1993 May 14;260(5110):879 [8098549.001]
  • [Cites] Int J Cancer. 1995 Oct 20;64(5):322-5 [7591304.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(5):425-32 [9272120.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1798-804 [11410522.001]
  • [Cites] Nat Med. 1995 Jun;1(6):578-82 [7585126.001]
  • [Cites] Ann Oncol. 1996 Jan;7(1):75-81 [9081396.001]
  • [Cites] Respiration. 2003 Jan-Feb;70(1):32-5 [12584388.001]
  • [Cites] Curr Drug Targets. 2000 Jul;1(1):85-99 [11475537.001]
  • [Cites] Lung. 2003;181(5):267-73 [14705770.001]
  • [Cites] Semin Oncol. 1993 Aug;20(4):326-37 [8102011.001]
  • [Cites] Jpn J Cancer Res. 1994 May;85(5):536-41 [7912240.001]
  • [Cites] Curr Probl Cancer. 1991 May-Jun;15(3):105-54 [1713139.001]
  • [Cites] J Biol Chem. 1998 Apr 10;273(15):8971-4 [9535882.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1929-34 [8980392.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):625-30 [8879378.001]
  • [Cites] Curr Drug Targets. 2001 Mar;2(1):57-77 [11465539.001]
  • [Cites] Int J Cancer. 1996 Apr 10;66(2):274-9 [8603824.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):251-7 [12177790.001]
  • [Cites] Int J Cancer. 1996 Jun 11;66(6):760-7 [8647646.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1059-63 [9831202.001]
  • [Cites] Int J Cancer. 2000 Oct 15;88(2):293-300 [11004683.001]
  • [Cites] Cancer. 1996 May 1;77(9):1947-55 [8646697.001]
  • [Cites] Int J Cancer. 1997 Sep 26;73(1):84-93 [9334814.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12 (5):450-8 [10975553.001]
  • [Cites] Cancer Sci. 2003 Apr;94(4):394-9 [12824911.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Eur J Cancer. 1994;30A(11):1705-9 [7833148.001]
  • (PMID = 15856298.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down






Advertisement